Unique structural features govern the activity of a human mitochondrial AAA+ disaggregase, Skd3

Highlights

- High-resolution structure of a PARL-Skd3-substrate complex
- Substrate-bound PARL-Skd3 hexamers stack head-to-head to form dodecamers
- Mechanisms by which PARL-Skd3 subunits collaborate to disaggregate proteins
- Mechanisms by which Skd3 mutations cause dominant and recessive forms of disease

Authors

Ryan R. Cupo, Alexandrea N. Rizo, Gabriel A. Braun, ..., Kushol Gupta, Daniel R. Southworth, James Shorter

Correspondence
daniel.southworth@ucsf.edu (D.R.S.), jshorter@pennmedicine.upenn.edu (J.S.)

In brief

Cupo et al. reveal the structure and mechanism of Skd3, a protein disaggregase found in mitochondria, which is critical for human health. These advances explain the inheritance patterns and suggest therapeutic strategies for debilitating diseases caused by mutations in Skd3.
Unique structural features govern the activity of a human mitochondrial AAA+ disaggregate, Skd3

Ryan R. Cupo,1,2,6 Alexandria N. Rizo,3,4,6 Gabriel A. Braun,5 Eric Tse,3 Edward Chuang,1,2 Kushol Gupta,1 Daniel R. Southworth,2,7,* and James Shorter1,2,7,8,*

1Department of Biochemistry and Biophysics, University of Pennsylvania, Philadelphia, PA, USA  
2Pharmacology Graduate Group, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA  
3Department of Biochemistry and Biophysics, University of California, San Francisco, San Francisco, CA, USA  
4Graduate Program in Chemical Biology, University of Michigan, Ann Arbor, MI, USA  
5Chemistry and Chemical Biology Graduate Program, Institute for Neurodegenerative Diseases, University of California, San Francisco, San Francisco, CA, USA  
6These authors contributed equally  
7Senior author  
8Lead contact  
*Correspondence: daniel.southworth@ucsf.edu (D.R.S.), jshorter@pennmedicine.upenn.edu (J.S.)

SUMMARY

The AAA+ protein, Skd3 (human CLPB), solubilizes proteins in the mitochondrial intermembrane space, which is critical for human health. Skd3 variants with defective protein-disaggregase activity cause severe congenital neutropenia (SCN) and 3-methylglutaconic aciduria type 7 (MGCA7). How Skd3 disaggregates proteins remains poorly understood. Here, we report a high-resolution structure of a Skd3-substrate complex. Skd3 adopts a spiral hexameric arrangement that engages substrate via pore-loop interactions in the nucleotide-binding domain (NBD). Substrate-bound Skd3 hexamers stack head-to-head via unique, adaptable ankyrin-repeat domain (ANK)-mediated interactions to form dodecamers. Deleting the ANK linker region reduces dodecamerization and disaggregase activity. We elucidate apomorphic features of the Skd3 NBD and C-terminal domain that regulate disaggregase activity. We also define how Skd3 subunits collaborate to disaggregate proteins. Importantly, SCN-linked subunits sharply inhibit disaggregase activity, whereas MGCA7-linked subunits do not. These advances illuminate Skd3 structure and mechanism, explain SCN and MGCA7 inheritance patterns, and suggest therapeutic strategies.

INTRODUCTION

Protein aggregation and aberrant phase transitions can be deleterious. Thus, specialized protein disaggregases have evolved to safely reverse protein aggregation and restore resolubilized proteins to native form and function (Fare and Shorter, 2021). These include ATP-independent systems, such as DAXX, TRIMs, and nuclear-import receptors, as well as ATP-dependent systems, including specific AAA+ (ATPases associated with diverse cellular activities) proteins, such as Hsp104 and Skd3 (human CLPB) (Cupo and Shorter, 2020b; Fare and Shorter, 2021; Huang et al., 2021; Zhu et al., 2020).

AAA+ proteins couple ATP hydrolysis to mechanical work to drive energetically challenging tasks, including protein disaggregation (Puchades et al., 2020). Thus, Hsp104, a hexameric, double AAA+ ring disaggregate found in all non-metazoan eu-karyotes, disassembles stable cross-β structures, disordered aggregates, toxic oligomers, and heat-induced condensates (DeSantis et al., 2012; Shorter and Southworth, 2019; Yoo et al., 2022). To disaggregate proteins, Hsp104 translocates polypeptides into its central channel using tyrosine-bearing pore loops that grip the substrate (Shorter and Southworth, 2019). Curiously, despite conferring neuroprotection when expressed in animals (Cushman-Nick et al., 2013; Lo Bianco et al., 2008), Hsp104 was lost during the transition from protozoa to metazoa, as was its mitochondrial counterpart, Hsp78 (Erives and Fassler, 2015). However, humans express Skd3 (human CLPB), a single AAA+ ring disaggregate found in the mitochondrial intermembrane space (IMS) (Antonicka et al., 2020; Botham et al., 2019; Hung et al., 2014; Rath et al., 2021; Rhee et al., 2013; Thevarajan et al., 2020), which first appears in evolution alongside Hsp104 and Hsp78 in the closest extant protozoan relatives of animals (Erives and Fassler, 2015). Skd3 is related to Hsp104 and Hsp78 via its HCLR clade AAA+ domain, but otherwise shares limited homology (Cupo and Shorter, 2020b; Erives and Fassler, 2015; Erzberger and Berger, 2006; Perier et al., 1995).

Skd3 maintains protein solubility in the IMS to ensure mitochondrial functionality (Chen et al., 2019; Cupo and Shorter, 2020b; Warren et al., 2022). Skd3 exhibits potent protein-disaggregase activity and is critical for human health (Cupo and
Autosomal dominant mutations in Skd3 that impair disaggregase activity cause severe congenital neutropenia (SCN) (Warren et al., 2022). SCN is a rare bone marrow failure syndrome that presents with impaired neutrophil maturation (Skokowa et al., 2017). Due to low neutrophil counts, SCN patients are prone to life-threatening infections, myelodysplastic syndromes, and acute myeloid leukemia (Skokowa et al., 2017). By contrast, autosomal recessive or distinct biallelic mutations in Skd3 that impair disaggregase activity underlie 3-methylglutaconic aciduria type 7 (MGCA7) (Cupo and Shorter, 2020b; Kanabus et al., 2015; Kiykim et al., 2016; Probiallelic mutations in Skd3 that impair disaggregase activity cause severe myelodysplastic syndromes, and acute myeloid leukemia (Sko- neutrophil maturation (Skokowa et al., 2017). Due to low neutro-rare bone marrow failure syndrome that presents with impaired myeloid abnormalities and delayed psychomotor development, which can be accompanied by cataracts, seizures, recurrent infections, and death a few weeks after birth (Wortmann et al., 2015). There are no effective therapeutics for severe MGCA7. Despite the importance of Skd3 for human health, little is known about Skd3 mechanism or structure (Cupo and Shorter, 2020b). Skd3 harbors an N-terminal mitochondrial targeting signal, which is cleaved by mitochondrial processing peptidase upon import into mitochondria (Wortmann et al., 2015). Skd3 then has an autoinhibitory hydrophobic peptide, which is removed by PARL, a rhomboid protease in the mitochondrial inner membrane (Saita et al., 2017; Spinazzi et al., 2019). Removal of this peptide increases Skd3 disaggregase activity by more than 10-fold (Cupo and Shorter, 2020b). Thus, Skd3 is only fully activated upon reaching its final destination in the IMS. After these processing events, the mature form of Skd3 contains an ankyrin-repeat domain (ANK), a nucleotide-binding domain (NBD) from the HCLR clade of the AAA+ family, and a short C-terminal domain (CTD) (Figure 1A). The ANK-AAA+ domain combination is an unusual feature of Skd3. Both the ANK and NBD are required for Skd3 disaggregase activity as deletion of either domain ablates activity (Cupo and Shorter, 2020b). How the ANK and NBD collaborate to power disaggregation is unknown. The ANK is comprised of two ankyrin repeats, a linker, and two more ankyrin repeats (Figure 1A). Ankyrin repeats adopt a helix-turn-helix conformation, which can enable specific protein-protein interactions (Kohl et al., 2003; Mosavi et al., 2004; Parra et al., 2015). Intriguingly, ankyrin repeats are a core component of an ATP-independent disaggregase, cpSRP43 (Jaru-Ampornpan et al., 2010, 2013). The Skd3 NBD is homologous to NBD2 of Hsp104 and bacterial ClpB (Cupo and Shorter, 2020b). Like Hsp104, Skd3 couples ATP hydrolysis to protein disaggregation, which requires conserved AAA+ motifs, such as Walker A, Walker B, and pore-loop tyrosines (Cupo and Shorter, 2020b). However, the Skd3 NBD contains an apomorphic insertion at residues L507–I534 that is not observed in any other AAA+ protein (Cupo and Shorter, 2020b). What role this insertion plays in Skd3 activity is unknown. Skd3 has an extended CTD that is patterned with acidic and basic residues (Cupo and Shorter, 2020b). By contrast, S. cerevisiae Hsp104 has an extended, acidic CTD that contributes to hexamerization (Mackay et al., 2008). How the CTD contributes to Skd3 function is unknown. SCN-linked mutations in Skd3 cluster in the NBD (Warren et al., 2022), whereas biallelic MGCA7-linked mutations are scattered throughout Skd3 (Wortmann et al., 2015). SCN-linked mutations impair ATPase and disaggregase activity (Warren et al., 2022). MGCA7-linked mutations impair disaggregase activity in a manner that predicts disease severity (Cupo and Shorter, 2020b). However, MGCA7-linked mutations do not always impair ATPase activity (Cupo and Shorter, 2020b). It is not understood why SCN-linked mutations are dominant-negative, whereas MGCA7-linked mutations are recessive. It is often assumed that Skd3 structure and mechanism closely resemble that of Hsp104/ClpB (Cupo-Chichi et al., 2015; Kanabus et al., 2015; Saunders et al., 2015). Yet, there are few studies of Skd3 disaggregase activity (Cupo and Shorter, 2020b; Mroz et al., 2020; Warren et al., 2022; Wortmann et al., 2021). Unlike Hsp104/ClpB, Skd3 does not require Hsp70 or Hsp40 to disaggregate disordered aggregates (Cupo and Shorter, 2020b). Moreover, Skd3 shares only ~20% sequence identity with Hsp104/ClpB and has only one domain, the NBD, in common with Hsp104/ClpB (Cupo and Shorter, 2020b; Erives and Fass- ler, 2015). Here, we employ cryoelectron microscopy (cryo-EM) and biochemical reconstitution to reveal Skd3 structure and mechanism. RESULTS PARL-Skd3 structure reveals a substrate-bound AAA+ spiral and flexible ANks To capture a substrate-bound state of Skd3, we included a model substrate casein, which binds to wild-type (WT) PARL-protease-activated Skd3 (PARL-Skd3; Figure 1A) (Cupo and Shorter, 2020b). PARL-Skd3 binding to FITC-labeled casein was assessed under different nucleotide conditions (Figure S1A). Binding was detected under all conditions, but PARL-Skd3 bound FITC-casein more effectively in the presence of non-hydrolyzable AMP-PNP (KD ~ 0.5 μM), or slowly hydrolyzable ATPγS (KD ~ 0.4 μM) in contrast to ADP or no nucleotide (Figure S1A). Thus, PARL-Skd3 differs from Hsp104, where only ATPγS facilitates avid polypeptide binding (Gates et al., 2017; Weaver et al., 2017). We assessed the oligomeric state of PARL-Skd3 by size-exclusion chromatography (SEC) (Figures 1B and S1B–S1D). Following incubation with ATPγS, AMP-PNP, or ADP without FITC-casein substrate, PARL-Skd3 exhibits a broad elution profile with peaks likely corresponding to dodecamers (792 kDa), hexamers (396 kDa), smaller oligomers, and monomers (66 kDa; Figure S1B). By contrast, in the presence of FITC-casein, PARL-Skd3 shifted toward dodecamers in all nucleotide conditions (Figures 1B and S1C). Thus, substrate binding by PARL-Skd3 promotes dodecamerization. Indeed, it has been independently established that PARL-Skd3 forms dodecamers (Spaulding et al., 2022; Wu et al., 2022). Moreover, Skd3 forms higher-order structures in cells, consistent with dodecamer formation (Thevarajan et al., 2020). Previously, we used ATPγS to stabilize substrate-bound states of Hsp104/ClpB (Gates et al., 2017; Rizo et al., 2019).
Figure 1. Structure of PARLSkd3

(A) PARLSkd3 domain architecture.

(B) SEC of PARLSkd3 incubated with ATPγS (solid) or ATPγS and FITC-casein (dashed). Vertical bars indicate molecular weight standards: thyroglobulin (669 kDa), ferritin (440 kDa), and ovalbumin (43 kDa), and are representative of PARLSkd3 dodecamer (gray), hexamer (cyan), or monomer (magenta) size. The gray bar also represents the fraction taken for cryo-EM analysis of PARLSkd3:casein.

(C) Cryo-EM 2D class averages of the PARLSkd3:casein:ATPγS complex showing representative side (left) and top (right) views. Scale bar, 100 Å.

(D) Overlay of low-pass filtered hexamer map and high-resolution sharpened map colored by domain as in (A).

(E and F) (E) Final 2.9-Å-resolution sharpened map and (F) molecular model colored by individual protomers (P1–P6), with substrate polypeptide (yellow) in the channel. See also Figures S1 and S2 and Video S1.
SEC-purified \textit{ParLSkd3}:casein forms stable complexes in the presence of ATPγS (Figures 1C and S1E). Reference-free 2D class averages show a variety of top and side views with well-resolved features (Figures 1C and S1E). Top views revealed two particle classes: a major class with a hexameric ring containing density in the central channel, and a minor class with a heptameric ring and an empty channel (Figure S1E). Top views of the hexameric ring appeared similar to substrate-bound Hsp104/CipB (Gates et al., 2017; Rizo et al., 2019), whereas side views revealed a distinct arrangement with two or three bands of density, indicating a stacked-ring arrangement of the \textit{ParLSkd3}:casein complex (Figures 1C and S1E). Notably, side views exhibit one strong band of density with well-resolved features, whereas the other bands are more diffuse, indicating flexibility or differential occupancy (Figure 1C).

Following 3D classification with four classes, we identified three distinct oligomeric arrangements: a hexameric double-ring complex that contains density in the channel (class 1), a hexameric three-ring complex that contains density in the central channel for one well-resolved ring (class 2), and a heptameric form containing two rings and an empty central channel (class 3) (Figure S1F). Given the low abundance of the heptameric ring and the absence of density for substrate, class 3 was not pursued further. Class 1 had the highest percentage of particles (41%) and a well-defined AAA+ ring. Thus, refinement was performed with class 1, resulting in a final resolution of 2.9 Å for the \textit{ParLSkd3}:casein complex (Figures S2A–2H; Table S1; Video S1). A molecular model for the hexameric ring comprised for the NBD, which refined to the highest resolution (~2.5 Å) in the map (Figure S2E), was determined using homology models generated by SWISS-Model (Waterhouse et al., 2018).

At an increased threshold, lower-resolution density extends from the N-terminal end of the NBDs and forms a second ring of separated and flexible globular structures (Figure 1D). These separated regions contrast with the extensive contact interfaces of the NBDs in the AAA+ ring (Figure 1D). Based on the molecular model of the NBDs and the position of the N-terminal AAA+ residues, we conclude that these separated regions are the N-terminal ANKs (Figures 1A and 1D). Given this architecture for a hexameric arrangement, we propose that the three-ring structures identified in the 2D class averages and in class 2 in the 3D classification are dodecamers comprised of two \textit{ParLSkd3} hexamers that interact via the ANKs, which form the middle ring of density (Figures 1C and S1F). Considering the flexibility of the ANKs and the second AAA+ ring, we postulate that, in addition to the hexamer form, class 1 likely contains dodecamers in which the second ring is poorly aligned and not visible in the reconstruction due to its flexibility. Indeed, when 2D classification of the class 1 particle is performed, weak density for a second AAA+ ring is identified in many side-view class averages, indicating a dodecamer (Figure S2A). Furthermore, SEC in tandem with multi-angle light scattering confirms \textit{ParLSkd3} dodecamers in solution (Figure S1G). We suggest that the active, substrate-bound form of \textit{ParLSkd3} likely exists in a dynamic equilibrium between hexamers and dodecamers.

The \textit{ParLSkd3} NBDs adopt a right-handed spiral, wherein five protomers directly contact substrate polypeptide along a 40-Å-length of the channel (Figures 1E and 1F; Video S1). These well-resolved protomers (P1–P5) are positioned in a helical arrangement, each with a rise of ~6 Å and rotation of ~60° along the substrate. Protomer P6 is at the seam interface between the lowest (P1) and highest (P5) substrate contact sites but is disconnected and has lower resolution, resulting in an asymmetric position within the spiral (Figures 1E and 1F). This architecture is akin to other substrate-bound AAA+ structures, including Hsp104/CipB (Gates et al., 2017; Rizo et al., 2019). Additional density is identified in protomers P3–P5 that extend from the small sub-domain of the NBD toward the adjacent clockwise protomer, and is likely the CTD (Figure 1D).

### Substrate contacts and NBD occupancy support a conserved, stepwise translocation model

Pore loop-substrate interactions and nucleotide states in the \textit{ParLSkd3} hexamer structure suggest a translocation mechanism. An extended polypeptide is well resolved in the \textit{ParLSkd3} channel and modeled as a 14-residue polyA peptide (Figure 2A). Based on previous work (Gates et al., 2017; Lopez et al., 2020; Rizo et al., 2019) and binding data (Figures S1A and S1D), we conclude that this extended polypeptide is a nonspecific portion of FITC-casein. The canonical pore loops (residues 429–432) for protomers P1–P5 directly bind the substrate backbone via a conserved YV motif (Y430 and V431; Figures 2A and 2B). These pore loops form a spiral staircase of contacts and comprise the primary substrate-binding sites identified in the structure, supporting their established role in translocation function (Shorter and Southworth, 2019). Indeed, mutation of the conserved tyrosine to alanine (Y430A) reduces ATPase activity and abolishes disaggregase activity (Cupo and Shorter, 2020b). We now find...
that V431G also reduces \textit{PARL}\textsubscript{Skd3} ATPase activity and abolishes disaggregase activity (Figures 2C and 2D). These results are consistent with our \textit{PARL}\textsubscript{Skd3} structure where Y430 and V431 directly engage substrate.

An additional spiral of substrate interactions at the channel exit is formed by secondary pore-loop motifs from protomers P2–P5 (Figures 2A and 2B). In \textit{PARL}\textsubscript{Skd3}, residues E416, R417, and H418 comprise this secondary pore loop, which is positioned in line with canonical YV loops above, but slightly further away (~9 Å) from the substrate backbone (Figures 2A and 2B). To define the role of the secondary pore loop, we generated \textit{PARL}\textsubscript{Skd3}R417A, which exhibited similar ATPase activity to \textit{PARL}\textsubscript{Skd3} (Figure 2C), but diminished disaggregase activity (Figure 2D). This loss of function is much more severe than that caused by equivalent mutations in Hsp104/ClpB (Howard et al., 2020; Rizo et al., 2019). Thus, the secondary pore loops play a more critical role in \textit{PARL}\textsubscript{Skd3} disaggregase activity than in Hsp104/ClpB.

The nucleotide-binding pockets in substrate-bound \textit{PARL}\textsubscript{Skd3} are positioned at inter-protomer interfaces with conserved AAA+ residues contacting the nucleotide (Figures 2E and S2I). For protomers P2–P5, these pockets are well resolved, revealing a bound ATP that is contacted by canonical Walker A (K387), Walker B (E455), sensor-1 (N496), and sensor-2 (R620) residues (Figures 2E and S2I). The Arg-finger (R561) is provided by the neighboring clockwise protomer, and positioned one step lower along the substrate, contacting the γ-phosphate of ATP in protomers P3–P5 (Figures 2E and S2I). For protomer P2, ATP is present, but the Arg-finger from P1 is positioned further away and not in contact, indicating an intermediate state (Figure S2I). Notably, ATP-bound states are only found for substrate-engaged protomers (Figures 2A and S2I). Density for the nucleotide is more poorly resolved in protomers P1 and P6 at the spiral seam (Figures 2A and S2I). The nucleotide is absent from P6, indicating an apo state, whereas P1 is likely ADP bound. Thus, post-hydrolysis states coincide with substrate release at the seam. Thus, \textit{PARL}\textsubscript{Skd3} may employ a conserved hydrolysis cycle similar to other AAA+ translocases (Gates et al., 2017; Puchades et al., 2021). This secondary structural model is predicted with high confidence based on the pLDDT score and low predicted align error values (Figures S3C and S3D). Resolution of the more poorly resolved NBD ring was insufficient to identify substrate in the channel, whereas density is present in the second NBD ring, which is likely casein contacted by pore loops from five protomers (Figure S3B). Conversely, in addition to the high-resolution AAA+ ring, the final map of the hexamer class (class 1) contains strong globular density extending from the N-terminal face that is likely the helical bundles of ankyrin repeats (Figure 1D). Thus, analysis of the full hexamer with the ANKs was further pursued with the class 1 map.

Structural information for the Skd3 ANK is unavailable. Thus, we used the Alpha-fold to model the ANK (Jumper et al., 2021). This secondary structural model is predicted with high confidence based on the pLDDT score and low predicted align error values (Figures S3C and S3D). Confidence was highest in the ANK and NBD domains (Figure S3D). Based on the Alpha-fold model, the ANK adopts four two-helix bundle structures that match canonical ANKs (Figure 3A).

**Figure 3.** The ANK mediates head-to-head contacts required for dodecamerization

(A) Schematic and model of \textit{PARL}\textsubscript{Skd3} ANK, colored by individual domains (left). Color-zoned map of substrate (yellow) present in the central channel of each AAA+ ring with \textit{PARL}\textsubscript{Skd3}A1-2 model docked in (middle, right).

(B) Overlay of two different classes resolved from focus classification around P3 identifying rotation of the ANK region (arrow).

(C and D) Overlay of different two classes resolved from focus classification around P3 identifying rotation of the ANK region (arrow).

(E) SEC of \textit{PARL}\textsubscript{Skd3} (black), \textit{PARL}\textsubscript{Skd3}1-2 (blue), \textit{PARL}\textsubscript{Skd3}3-4 (green), and \textit{PARL}\textsubscript{Skd3}3-4 (red) incubated with ATPγS and casein. Vertical bars indicate molecular weight standards: thyroglobulin (669 kDa), ferritin (440 kDa), and ovalbumin (43 kDa), and are representative of \textit{PARL}\textsubscript{Skd3} dodecamer (gray), hexamer (cyan), or monomer (magenta) size.

(F) ATPase activity of \textit{PARL}\textsubscript{Skd3}, \textit{PARL}\textsubscript{Skd3}1-2, \textit{PARL}\textsubscript{Skd3}3-4, and \textit{Hsp104}. ATPase activity was compared with \textit{PARL}\textsubscript{Skd3} using one-way ANOVA and a Dunnett’s multiple comparisons test (n = 3–6, individual data points shown as dots, bars are mean ± SEM, ****p < 0.0001).

(G) Luciferase disaggregase activity of \textit{PARL}\textsubscript{Skd3}, \textit{PARL}\textsubscript{Skd3}1-2, \textit{PARL}\textsubscript{Skd3}3-4, and \textit{Hsp104} plus Hsp70 and Hsp40. Luciferase activity was normalized to Hsp104 plus Hsp70 and Hsp40. Disaggregase activity was compared with \textit{PARL}\textsubscript{Skd3} using one-way ANOVA and a Dunnett’s multiple comparisons test (n = 3, individual data points shown as dots, bars show mean ± SEM, ****p < 0.0001).

(H) 2D class averages of \textit{PARL}\textsubscript{Skd3}1-2 (top) and \textit{PARL}\textsubscript{Skd3} (bottom) with the middle band of ANK density indicated (*). Note that the triple-hexamer arrangement (top right) is only found for \textit{PARL}\textsubscript{Skd3}A1-2. Scale bar, 100 Å.

(I) Dodecamer map and model of \textit{PARL}\textsubscript{Skd3}A1-2 colored by individual domains (left). Color-zoned map of substrate (yellow) present in the central channel of each AAA+ ring with \textit{PARL}\textsubscript{Skd3}A1-2 model docked in (middle, right).

(J) Dodecamer map and model of \textit{PARL}\textsubscript{Skd3}A1-2 showing ankyrin-repeat interactions across hexamers. See also Figure S3 and Video S2.
Luciferase activity was normalized to the PARLSkd3 30 min time point. Luciferase activity was compared with PARLSkd3 using one-way ANOVA and a Dunnett’s multiple comparisons test (n = 3, individual data points shown as dots, bars show mean portion of the N-terminal ANK is required to maintain PARLSkd3 ure 3G), indicating that the ANK enables PARLSkd3 to efficiently couple ATP hydrolysis to protein disaggregation. Deletion of the linker had the largest effect (Figure 3G). PARLSkd3L is impaired in dodecamer formation (Figure 3E). Thus, dodecamerization may promote disaggregation activity. We suggest that the ANKs play multiple roles in protein disaggregation, including dodecamerization, potentially supported by the linker, and substrate engagement mediated by ankyrin repeats 1–4 (Wu et al., 2022).

EM indicated that PARL Skd33-1-2 forms more stable dodecamers than PARL Skd33-4 and PARL Skd33-4. Thus, we investigated PARL Skd33-1-2 further by cryo-EM. 2D averages of PARL Skd33-1-2 show a well-resolved middle ring of ANKs that is smaller in diameter than PARL Skd3 (Figure 3H). 3D classification of PARL Skd33-1-2 identified three distinct forms. Class 1 and class 2 are dodecamers with different relative positions of the AAA+ rings, whereas class 3 is a trimmer of hexamers (Figures S3H and S3J). Notably, class 1 was pursued due to the more homogeneous arrangement of the ANK ring and improved density for the second AAA+ ring compared with the PARL Skd3 complex (Figures 3I, 3J, and S3–S3M). Notably, we identify density in the two AAA+ channels that corresponds to the substrate, indicating that both AAA+ rings can bind substrate in the dodecamer (Figure 3I). Although the resolution was low (∼9 Å), a dodecameric model with ankyrin repeats 3 and 4 fit well into the density, and revealed head-to-head ANK contacts around the central ring that mediate dodecamer formation (Figures 3I and 3J; Table S1; Video S2). Given that PARL Skd33-3-4 can also form dodecamers, as can PARL Skd33-4 to a lesser extent (Figure 3E), our findings indicate plasticity in how the ANK mediates cross-contacts to form dodecamers. We suggest that deleting specific ankyrin repeats or the linker reduces this interactive plasticity and disaggregate activity (Figure 3G).

A unique insertion within the PARL Skd3 NBD regulates the AAA+ motor

Skd3 contains an insertion (residues L507-I534) within the NBD that is conserved across Skd3 homologs but is not found in Hsp104 or other HCLR class AAA+ proteins (Figures 4A and S4A). We modeled part of the insertion, but 17 residues (517–533) were missing (Figures 4B and S4B). The insertion extends past the loop that is found in Hsp104 (Figure S4C) and protrudes from the hexamer exterior (Figure 4B). Purified PARL Skd33ALS70-134 formed large oligomers that are not observed for PARL Skd3 (Figure 4D). However, upon addition of casein, PARL Skd33ALS70-134 forms primarily dodecamers (Figure 4D). PARL Skd33ALS70-134 had elevated ATPase and disaggregate activity compared with PARL Skd3 (Figures 4C and 4D). Thus, the L507-I534 insertion is a regulatory element, which slows PARL Skd3 ATPase activity and tunes disaggregate activity. The location of the L507-I534 insertion on the ANKs play multiple roles in protein disaggregation, including dodecamerization, potentially supported by the linker, and substrate engagement mediated by ankyrin repeats 1–4 (Wu et al., 2022).
Figure 5. PARLskd3 is functional at low ATP concentrations

(A) Michaelis-Menten plot of PARLskd3 ATPase activity. $V_{\text{max}} \sim 23.6 \text{ min}^{-1}$ and $K_M \sim 64.6 \mu M$ ($n = 3$, values are means ± SEM).

(B) Luciferase disaggregase activity of PARLskd3 at various ATP:buffer ratios. ATP concentrations used were 12:0 (5 mM), 11:1 (4.58 mM), 10:2 (4.17 mM), 9:3 (3.75 mM), 8:4 (3.33 mM), 7:5 (2.92 mM), 6:6 (2.5 mM), 5:7 (2.08 mM), 4:8 (1.67 mM), 3:9 (1.25 mM), 2:10 (0.83 mM), 1:11 (0.42 mM), and 0:12 (0 mM). Disaggregase activity was normalized to PARLskd3 plus ATP ($n = 3$, individual data points shown as dots, bars show mean ± SEM).

(C) Luciferase disaggregase activity of PARLskd3 at various ATP:ADP ratios where the total nucleotide concentration was 5 mM. Disaggregase activity was normalized to PARLskd3 plus ATP ($n = 3$, individual data points shown as dots, bars show mean ± SEM).

(D) Luciferase disaggregase activity of PARLskd3 at a constant concentration of ATP (5 mM) and increasing ADP concentrations. Disaggregase activity was normalized to PARLskd3 plus ATP ($n = 3$, values are means ± SEM).

(legend continued on next page)
hexamer exterior could provide a site for regulatory factors to bind or post-translationally modify Skd3.

**Deletion of the PARLSkd3 CTD mildly stimulates ATPase activity**

Deletion of the extended, acidic CTD of *S. cerevisiae* Hsp104 results in hexamerization defects (Mackay et al., 2008). Like Hsp104 and in contrast to other HCLR clade AAA+ proteins, Skd3 has an extended CTD from residues 660 to 707 (Figure 4E) (Cupo and Shorter, 2020b). However, the Skd3 CTD is patterned with acidic and basic residues, whereas the Hsp104 CTD is acidic (Cupo and Shorter, 2020b). In the PARLSkd3 reconstruction, 14 residues of the CTD were evident in protomers P3–P5 (Figure 1D). These CTD residues fit along the side of the adjacent protomer and are near helices D2 and D3 (Figures 4F and S2F). Residues within ~4 Å of the CTD include E340 and Q341 in D2, and R362 in D3. Additional contacts may occur with helix E3 of the same protomer (Figures 4F and S2F). We purified PARLSkd3 lacking the CTD (PARLSkd3Δ660-707), which formed hexamers and dodecamers similar to PARLSkd3 (Figures 1A and S4E). PARLSkd3Δ660-707 exhibited mildly increased ATPase activity (Figure 4G), whereas disaggregase activity was similar to PARLSkd3 (Figure 4D). Thus, the CTD enables efficient coupling of PARLSkd3 ATPase and disaggregase activity. We suggest that the PARLSkd3 CTD plays a different role than the Hsp104 CTD.

**PARLSkd3 is functional at low ATP concentrations**

Mitochondria maintain lower ratios of ATP:ADP and lower ATP concentrations than the cytoplasm (Gellerich et al., 2002; Heldt et al., 1972; Imamura et al., 2009). To determine how PARLSkd3 might operate under various nucleotide conditions, we established that PARLSkd3 ATPase activity has a *V*max of ~24 min⁻¹ and a *Km* of ~65 μM (Figure 5A). By contrast, the *Km* of Hsp104 is ~5–11 mM (Grimminger et al., 2004; Schirmer et al., 1998). PARLSkd3 maintains disaggregase activity at low ATP concentrations, including ~50% disaggregase activity at the lowest ATP concentration tested (0.434 mM) (Figure 5B). Thus, PARLSkd3 is likely adapted to operate effectively at lower ATP concentrations than Hsp104.

**PARLSkd3 disaggregase activity is inhibited by ADP**

Hsp104 is sharply inhibited by mixing ADP with ATP (Grimminger et al., 2004; Hattendorf and Lindquist, 2002; Klosowska et al., 2016). Even a 5:1 ATP:ADP ratio diminishes Hsp104 activity (Klosowska et al., 2016). To test the effect of ADP on PARLSkd3, we assessed PARLSkd3 disaggregase activity under different ATP:ADP ratios while keeping the total nucleotide concentration constant. PARLSkd3 is inhibited by ADP, but maintains ~50% activity at a 5:1 ATP:ADP ratio (Figure 5C), which inactivates Hsp104 (Klosowska et al., 2016). The half-maximal inhibitory concentration (IC50) of ADP at a constant concentration of ATP (5 mM) was ~1.2 mM (Figure 5D). Thus, PARLSkd3 is less sensitive than Hsp104 to inhibition by ADP and is likely adapted to function at the lower ATP:ADP ratios found in mitochondria.

**PARLSkd3 disaggregase activity is sharply inhibited by ATPγS**

Next, we assessed how PARLSkd3 disaggregase activity is affected by the slowly hydrolyzable ATP analog, ATPγS. Like Hsp104, PARLSkd3 is inactive in the presence of ATPγS as the sole nucleotide (Cupo and Shorter, 2020b; DeSantis et al., 2012). However, Hsp104 disaggregase activity against disordered aggregates can be stimulated at specific ratios of ATP:ATPγS (~3:1–1:5), whereas Hsp104 disaggregase activity against amyloid is inhibited by ATPγS in the presence of ATP (DeSantis et al., 2012). Thus, Hsp104 employs distinct mechanisms of subunit collaboration to disassemble disordered aggregates versus amyloid (DeSantis et al., 2012). To assess the effect of ATPγS on PARLSkd3, we measured PARLSkd3 disaggregase activity under different ATP:ATPγS ratios while keeping the total nucleotide concentration constant. PARLSkd3 is sharply inhibited by ATPγS (Figure 5E). Even an 11:1 ATP:ATPγS ratio inhibits PARLSkd3 (Figure 5E). The IC50 of ATPγS at a constant concentration of ATP (5 mM) was ~242 μM (Figure 5F). Thus, in contrast to Hsp104 (DeSantis et al., 2012), PARLSkd3 disaggregase activity against disordered aggregates is not stimulated by ATP:ATPγS mixtures. The distinctive responses of PARLSkd3 to ADP and ATPγS reveal differences in how PARLSkd3 and Hsp104 disaggregase activity are regulated. The sharp inhibition of PARLSkd3 disaggregase activity by ATPγS indicates that PARLSkd3 is sensitive to individual subunits that hydrolyze ATP slowly.

**PARLSkd3 is a subglobally cooperative protein disaggregate**

Next, to define mechanochemical coupling mechanisms of PARLSkd3, we used a mutant subunit doping strategy to assess how individual PARLSkd3 subunits contribute to ATPase and disaggregase activity. We modeled Skd3 as a hexamer, which forms the functional AAA+ cassette (Figure 2E). In this strategy, mutant PARLSkd3 subunits defective in ATP hydrolysis or subunit binding are mixed with WT PARLSkd3 subunits to generate heterohexameric ensembles according to a binomial distribution dictated by the WT:mutant ratio (Figure 6A). As mutant PARLSkd3 concentration in the mixture increases, the probability of mutant PARLSkd3 incorporation into a PARLSkd3 hexamer increases (Figure 6A). This approach has revealed mechanochemical coupling mechanisms of other NTPases, including Hsp104/ClpB (DeSantis et al., 2012; Moreau et al., 2007; Shivhare et al., 2019; Werbeck et al., 2008).

This strategy depends on robust formation of randomized heterohexameric ensembles, which requires exchange of subunits between WT and mutant PARLSkd3 hexamers such that mutant

---

(E) Luciferase disaggregase activity of PARLSkd3 at various ATP:ATPγS ratios where the total nucleotide concentration was 5 mM. Disaggregase activity was normalized to PARLSkd3 plus ATP (n = 3, individual data points shown as dots, bars show mean ± SEM).

(F) Luciferase disaggregase activity of PARLSkd3 at a constant concentration of ATP (5 mM) and increasing ATPγS concentrations. Disaggregase activity was normalized to PARLSkd3 plus ATP (n = 3, data shown as mean ± SEM).
Figure 6. Skd3 is a subglobally cooperative disaggregase

(A) Theoretical PARLSkd3 hexamer ensembles containing zero (black), one (blue), two (green), three (orange), four (red), five (purple), and six (yellow) mutant subunits as a function of the fraction of mutant subunit.

(B) Theoretical PARLSkd3 activity curves where one or more (blue), two or more (red), three or more (green), four or more (purple), five or more (light blue), or six (orange) mutant subunits ablate hexamer activity. In a probabilistic model, six mutant subunits per hexamer ablate activity. In a subglobally cooperative model, two to five mutant subunits per hexamer ablate activity. In a globally cooperative model, one mutant subunit per hexamer ablates activity.

(C and D) Protomer P2 with nucleotide and K387 shown in (C) or substrate and Y430 shown in (D).

(E and F) ATPase activity of PARLSkd3 mixed with various ratios of PARLSkd3K387A (E) or PARLSkd3Y430A (F). ATPase activity was normalized to PARLSkd3 (n = 3, black dots are means ± SEM).

(G and H) Luciferase disaggregase activity of PARLSkd3 mixed with various ratios of PARLSkd3K387A (G) or PARLSkd3Y430A (H). Disaggregase activity was normalized to PARLSkd3 (n = 3, black dots are means ± SEM). See also Figure S5.
subunits mix equally well into heterohexamers as WT (Figure 6A). To assess subunit mixing, we labeled PARLSkd3 with Alexa 488 or Alexa 594, which can form a Förster resonance energy transfer (FRET) pair. Labeled PARLSkd3 retained ATPase and disaggregase activity (Figures S5A and S5B). We mixed Alexa 488-labeled PARLSkd3 and Alexa 594-labeled PARLSkd3 in the absence of substrate, where the hexamer is more populated (Figures S1B and S1C). Hence, FRET likely reflects subunit mixing within the hexamer. For WT PARLSkd3, a robust FRET signal was observed within a few minutes, indicating subunit mixing on the minute timescale similar to Hsp104 (Figure S5D) (DeSantis et al., 2012). Thus, PARLSkd3 forms dynamic hexamers that exchange subunits on the minute timescale.

Importantly, mutant PARLSkd3 subunits were effectively incorporated into WT PARLSkd3 hexamers (Figure S5D). PARLSkd3K387A (Walker A) subunits likely incorporate into WT PARLSkd3 hexamers as effectively as WT PARLSkd3 subunits, whereas PARLSkd3Y430A (pore loop) subunits incorporated into WT PARLSkd3 hexamers ~16% less efficiently than WT PARLSkd3 subunits (Figure S5D). Thus, specific mutant PARLSkd3 subunits incorporate effectively into WT PARLSkd3 hexamers, indicating that the PARLSkd3 mechanism can be probed via mutant doping studies.

This rapid subunit exchange enables formation of PARLSkd3 heterohexamer ensembles comprised of WT and mutant subunits according to a binomial distribution (Figure 6A). Using this distribution, we can predict how PARLSkd3 activity would be inhibited at various WT:mutant ratios if a specific number of PARLSkd3 mutant subunits activate the hexamer (Figure 6B). For example, if all six PARLSkd3 subunits must work together, then one mutant subunit would abolish hexamer activity (Figure 6B, dark blue curve). By contrast, if the activity of a single PARLSkd3 subunit within the hexamer is sufficient, then some activity would still be observed with five mutant subunits per hexamer, and only six mutant subunits would abolish activity (Figure 6B, orange line). By comparing experimental data with theoretical plots, we can determine whether subunit collaboration within PARLSkd3 hexamers is probabilistic (six mutant subunits abolish activity), subglobally cooperative (two to five mutant subunits abolish activity), or globally cooperative (one mutant subunit abolishes activity).

We titrated PARLSkd3 with buffer over the concentration range of the subunit doping ATPase assay and found a linear decline in ATPase activity (Figure S5E). Thus, when titrating mutant PARLSkd3, a sharper than linear decline in ATPase activity indicates inhibitory effects of mutant subunits incorporated into hexamers. We also titrated PARLSkd3 with buffer over a range of concentrations to assess disaggregase activity (Figure S5F). We selected saturating PARLSkd3 concentrations to ensure that any observed effects on disaggregase activity upon mixing WT and mutant are not caused by a mere decrease in the concentration of WT PARLSkd3 (DeSantis et al., 2012; Werbeck et al., 2008). PARLSkd3K387A (Walker A) and PARLSkd3Y430A (pore loop) are inactive for ATPase and disaggregase activity (Cupo and Shorter, 2020b). The Walker A residue, K387, contacts the β- and γ-phosphate of ATP and a K387A mutation is predicted to reduce ATP binding and hydrolysis (Figure 6C) (Puchades et al., 2020). The pore-loop tyrosine, Y430, engages substrate, and a Y430A mutation is predicted to reduce substrate binding (Figures 2B and 6D) (Cupo and Shorter, 2020b). We assembled heterohexamer ensembles of PARLSkd3 with PARLSkd3K387A (Walker A) or PARLSkd3Y430A (pore loop). PARLSkd3K387A (Walker A) subunits inhibited PARLSkd3 ATPase activity in a manner that suggested the incorporation of approximately three to five mutant subunits inactivates the hexamer (Figure 6E). Thus, basal Skd3 ATPase activity appears to be subglobally cooperative. By contrast, titrating PARLSkd3Y430A (pore loop) subunits did not affect PARLSkd3 ATPase activity any more than dilution in buffer (Figure 6F). Hence, the ATPase activity of the PARLSkd3 hexamer is more resistant to pore-loop mutant subunits than Walker A mutant subunits. Our findings contrast with observations made with Hsp104 (DeSantis et al., 2012), where Walker A mutant subunits do not affect the ATPase activity of the hexamer more than dilution in buffer, and pore-loop mutant subunits have no effect (DeSantis et al., 2012). Thus, Hsp104 and PARLSkd3 display distinct subunit cooperativity with respect to ATP hydrolysis.

We next examined how PARLSkd3K387A (Walker A) and PARLSkd3Y430A (pore loop) subunits affected PARLSkd3 disaggregase activity. Incorporation of two PARLSkd3K387A (Walker A) subunits is sufficient to inactivate the PARLSkd3 hexamer (Figure 6G). Thus, PARLSkd3 hexamers are sensitive to individual subunits that are unable to bind or hydrolyze ATP due to a defective Walker A motif. This finding reinforces our previous observation that PARLSkd3 disaggregase activity is sharply inhibited by the slowly hydrolyzable ATP analog, ATPγS (Figures 5E and 5F). By contrast, five PARLSkd3Y430A (pore loop) subunits are needed to inactivate the PARLSkd3 hexamer (Figure 6H). Even though PARLSkd3Y430A has reduced ATPase activity (Cupo and Shorter, 2020b), this ATPase defect is more readily buffered by WT

**Figure 7. SCN-linked subunits inhibit PARLSkd3 activity more severely than MGC7-linked PARLSkd3 subunits**

(A) Location of MGC7-linked biallelic mutations in Skd3 (top). Model of protomers P2 and P3 with MGC7-linked mutations colored in red (bottom). (B) Model of back protomers colored by individual protomers (left). Interaction interface of residue R475 from protomer P2 and residue R408 from protomer P3. (C) Location of SCN-linked mutations in Skd3 (top). Model of protomers P2 and P3 with SCN-linked mutations colored in red. (D) Model of back protomers colored by individual protomers (left). Interaction interface of residues E557 and R561 of protomer P2 and residues N496 and R620 from protomer P3 within the nucleotide-binding pocket of protomer P3. (E–H) ATPase activity of PARLSkd3 mixed with various ratios of PARLSkd3R475Q (E), PARLSkd3R408G (F), PARLSkd3N496K (G), or PARLSkd3R561G (H). ATPase activity was normalized to PARLSkd3 (n = 3, black dots are means ± SEM). (I–L) Luciferase disaggregase activity of PARLSkd3 mixed with various ratios of PARLSkd3R475Q (I), PARLSkd3R408G (J), PARLSkd3N496K (K), or PARLSkd3R561G (L). Disaggregase activity was normalized to PARLSkd3 (n = 3, black dots are means ± SEM). (M) PARLSkd3 hexamers containing a mixture of WT and MGC7-linked subunits are typically active disaggregases. (N) PARLSkd3 hexamers containing a mixture of WT and SCN-linked subunits are typically less active disaggregases. See also Figure S6.
subunits upon incorporation into PARLSkd3 hexamers (Figure 6F). Thus, insufficient substrate binding by the pore loops must contribute to inhibition by PARLSkd3Y430A subunits. We suggest that PARLSkd3 utilizes a subglobally cooperative mechanism to disaggregate disordered luciferase aggregates. Specifically, at least five subunits must have a functional Walker A motif to bind and hydrolyze ATP and at least two subunits must be able to engage substrate tightly via Y430 for productive luciferase disaggregation activity. Our findings illustrate that PARLSkd3 hexamers display robustness and can buffer a defined number of specific mutant subunits. For example, PARLSkd3 hexamers can tolerate one subunit with a defective Walker A motif, and four subunits with a defective pore loop, and still drive luciferase disaggregation. This variable robustness has implications for SCN and MGCA7 etiology.

SCN-linked subunits inhibit PARLSkd3 activity more severely than MGCA7-linked PARLSkd3 subunits

We surveyed the location of disease-linked mutations in the Skd3 structure. Biallelic MGCA7-linked mutations are dispersed throughout Skd3 (Figure 7A) (Wortmann et al., 2015). MGCA7-linked mutations are found in the MTS, ANK, NBD, and CTD (Figure 7A). T268M, A269T, and Y272C cluster in ankyrin repeat 3 (Figure 7A). Specifically, residues T268 and A269 lie near the N-terminal portion of the first α helix in ankyrin repeat 3 (Figure S3F). Mutations at T268 and A269 might destabilize the α helix and disrupt ankyrin repeat 3 (Mosavi et al., 2002). MGCA7-linked mutations are also found in the large (e.g., M411I, R460P, C486R, and E501K) and small (e.g., A591V, R628C, and R650P) NBD subdomains (Figure 7A). Some MGCA7-linked NBD mutations, such as R475Q and R408G, are in residues that make interprotomer contacts (Figure 7B).

By contrast, SCN-linked mutations are found exclusively in the NBD and cluster within the nucleotide-binding pocket (Figures 7C and 7D) (Warren et al., 2022). Most of the SCN-linked mutations are in canonical AAA+ motifs. N496K mutates the sensor-1 motif, which coordinates the attacking water molecule relative to the γ-phosphate of ATP (Figures 2E, S2I, and 7D) (Puchades et al., 2020). R561G mutates the Arg finger, which contacts the γ-phosphate of ATP in the nucleotide-binding pocket of the adjacent protomer and is key for ATP hydrolysis (Figures 2E, S2I, and 7D) (Puchades et al., 2020). R620C mutates the sensor-2 motif, which contacts the β- and γ-phosphates of ATP (Figures 2E, S2I, and 7D) (Puchades et al., 2020). T388K is directly adjacent to the Walker A motif, is highly conserved among other HCLR clade AAA+ proteins, and faces into the nucleotide-binding pocket (Figures 2E and 7C). Finally, E557K lies within a conserved stretch of residues near the Arg finger and contacts the nucleotide (Figures 7C and 7D).

MGCA7-linked mutations impair disaggregate activity in a way that predicts disease severity (Cupo and Shorter, 2020b). However, MGCA7-linked mutations do not always impair ATPase activity (Cupo and Shorter, 2020b). By contrast, SCN-linked mutations invariably impair ATPase and disaggregate activity (Warren et al., 2022). It is not understood why SCN-linked mutations are dominant negative, whereas MGCA7-linked mutations are recessive. To assess how severely MGCA7-linked and SCN-linked variants affect WT PARLSkd3 activity, we selected three MGCA-7 linked variants (R408G, R475Q, and A591V) and three SCN-linked variants (N496K, R561G, and R620C) for subunit doping studies (Figures 7A–7D) (Pronicka et al., 2017; Warren et al., 2022). All of these mutations severely impair disaggregate activity (Cupo and Shorter, 2020b; Warren et al., 2022). Likewise, these disease-linked variants have diminished ATPase activity, with the exception of the MGCA7-linked variant PARLSkd3R408G, which retains ~20% ATPase activity (Cupo and Shorter, 2020b; Warren et al., 2022).

We assessed the ability of the disease-linked PARLSkd3 variants to form hexamers and dodecamers in the presence of ATP:S and absence of substrate. Unlike PARLSkd3, which was shifted toward the hexameric form, two of the MGCA7-linked variants, PARLSkd3R408G and PARLSkd3R475Q, were shifted toward dodecamers (Figure S6A). By contrast, MGCA7-linked PARLSkd3R491V was shifted to lower-molecular-weight oligomers (Figure S6A). PARLSkd3R491V formed some hexamers, but dodecamers were reduced (Figure S6A). The SCN-linked variant, PARLSkd3N496K, was shifted toward hexamers like PARLSkd3 (Figure S6B). The remaining SCN-linked variants, PARLSkd3R561G and PARLSkd3R620C, were shifted toward dodecamers (Figure S6B).

To test how severely disease-linked variants affected WT PARLSkd3 activity, we mixed each disease-linked variant and WT PARLSkd3 and assessed ATPase activity. FRET studies showed that disease-linked PARLSkd3 subunits were effectively incorporated into WT PARLSkd3 hexamers (Figures S6C and S6D). Addition of the MGCA7-linked variant PARLSkd3R475Q to PARLSkd3 revealed that six PARLSkd3R475Q subunits are required to reduce ATPase activity to the same level as PARLSkd3R475Q (Figure 7E). PARLSkd3R408G retains ~20% of WT ATPase activity and five PARLSkd3R408G subunits per hexamer reduced ATPase activity to this level (Figure 7F). Likewise, five PARLSkd3R491V subunits per hexamer are required to eliminate ATPase activity (Figure S6E). Thus, MGCA7-linked subunits have mild inhibitory effects on the ATPase activity of WT subunits.

The inhibitory effect of SCN-linked subunits on ATPase activity was more severe. Incorporation of two to four PARLSkd3R491K subunits inactivated the hexamer (Figure 7G). Moreover, three to four SCN-linked PARLSkd3R561G subunits or four PARLSkd3R620C subunits inactivated the hexamer (Figures 7H and S6G). Thus, SCN-linked subunits more sharply inhibit the ATPase activity of WT subunits than MGCA7-linked subunits.

We assessed how MGCA7-linked subunits affected PARLSkd3 disaggregase activity in mixing experiments. Six MGCA7-linked PARLSkd3R408G, PARLSkd3R475Q, or PARLSkd3A591V subunits were needed to eliminate PARLSkd3 disaggregase activity (Figures 7I, 7J, and S6F). Strikingly, PARLSkd3R491V subunits barely affected disaggregate activity even when three mutant subunits were incorporated into the hexamer (Figure S6F). Thus, even one WT PARLSkd3 subunit in an otherwise PARLSkd3R408G, PARLSkd3R475Q, or PARLSkd3A591V hexamer enables disaggregation. Indeed, MGCA7-linked mutant subunits have only minor effects on the disaggregate activity of WT subunits within the hexamer. The strong buffering activity of WT PARLSkd3 subunits explains why MGCA7-linked mutations are biallelic and recessive.
Finally, we assessed how SCN-linked subunits affected PARLSkd3 disaggregase activity in mixing experiments (Figures 7K, 7L, and S6H). Incorporation of only two SCN-linked PARLSkd3R561G subunits inactivated the hexamer (Figure 7K). Only one or two PARLSkd3R620C subunits were required to inactivate the hexamer (Figure 7L). Finally, incorporation of three SCN-linked PARLSkd3R561G subunits inactivated the hexamer (Figure S6H). Generally, SCN-linked subunits have a sharper inhibitory effect on WT PARLSkd3 than MGCA7-linked subunits (Figures 7E–7L and S6E–S6J). These results explain why SCN-linked mutations are dominant negative and typically monoallelic.

**DISCUSSION**

Here, we describe PARLSkd3 (human CLPB) structure and define mechanisms by which PARLSkd3 disaggregates proteins. PARLSkd3 forms a hexamer with an asymmetric seam between protomers P1 and P6, analogous to other AAA+ proteins, such as Hsp104/CipB and ClpA (Gates et al., 2017; Lopez et al., 2020; Rizo et al., 2019). PARLSkd3 hexamers engage substrate in their central channel via pore-loop interactions in the NBD. Indeed, PARLSkd3 may employ a conserved translocation mechanism of other AAA+ translocases (Gates et al., 2017; Puchades et al., 2017; Rizo et al., 2019). Mutation of conserved primary pore-loop residues that engage the substrate (e.g., Y430 and V431) reduce disaggregase activity (Cupo and Shorter, 2020b). Interestingly, mutations at V431 are found in humans (V431D, V431A, and V431I) with low frequency, although none of the known carriers are homozygous (Karczewski et al., 2020). We predict that specific biallelic mutations to V431 would be highly pathogenic.

One of the most prominent features of the PARLSkd3 structure is the dodecamer, which is created by two hexamers making head-to-head contacts via the ANK domain. While our paper was under review, it has been independently established that PARLSkd3 forms dodecamers (Spaulding et al., 2022; Wu et al., 2022). Moreover, Skd3 forms higher-order structures in cells, consistent with dodecamerization (Thevarajan et al., 2020). The type of dodecameric arrangement formed by PARLSkd3 is unusual for a AAA+ protein, but the AAA+ Lon protease can form dodecamers, which exhibit reduced activity for some substrates (Vieux et al., 2013). By contrast, our findings suggest that dodecamer formation may enhance PARLSkd3 disaggregase activity. PARLSkd3 hexamers and dodecamers are in dynamic equilibrium, but the dodecamer predominates upon polypeptide binding. The head-to-head ANK contacts could concentrate PARLSkd3 dodecamerges on the aggregate surface and enable stronger pulling forces by maximizing the number of hexamers, simultaneously processing the substrate. Indeed, PARLSkd3ΔL, which lacks the ANK linker region, exhibited reduced dodecamerization and reduced disaggregase activity, whereas ATPase activity was unaffected. Moreover, PARLSkd3ΔL507-1534, which lacks the insertion in the NBD, exhibits increased dodecamerization, disaggregase activity, and ATPase activity. Thus, dodecamerization might enhance PARLSkd3 disaggregase activity.

The ankyrin repeats are an unusual feature of PARLSkd3. The ANK and NBD are required for Skd3 disaggregase activity (Cupo and Shorter, 2020b). Alpha-fold predicts that N-terminal ankyrin repeats 1 and 2 stack on the C-terminal ankyrin repeats 3 and 4, with the largely disordered linker excluded (Figure 3A). Deletion of ankyrin repeats 1 and 2, the linker, or ankyrin repeats 3 and 4 from the ANK reduces disaggregase activity, but not ATPase activity. However, each of these deletion variants retained ~20%–45% PARLSkd3 disaggregase activity, indicating that the remaining ankyrin repeats and linker can support some activity. The linker region helps to promote dodecamer formation, whereas deletion of ankyrin repeats 1 and 2 or 3 and 4 does not perturb dodecamerization. The ankyrin repeats likely also play a role in substrate engagement (Wu et al., 2022) or dis-aggregate plasticity analogous to the Hsp104 N-terminal domain (Sweeney et al., 2015).

Interestingly, several Skd3 transcript variants are found in humans, which differ only in the ANK (The UniProt Consortium, 2021). Residues R152-N180, corresponding to part of ankyrin-repeats 1 and 2, are absent in transcript variant 3. Residues D216-G245, corresponding to the middle section of the linker, are absent in transcript variants 2 and 3. The functional consequences of these transcript variants are not clear, but both deletions correspond to the length of almost exactly one ankyrin repeat (Figure 1A). Thus, cells may tune the level of Skd3 disaggregase activity via translation of these distinct Skd3 transcripts.

Mutant subunit-doping studies suggest that PARLSkd3 uses a subglobally cooperative mechanism (i.e., two to five subunits collaborate) to disassemble disordered luciferase aggregates. PARLSkd3 disaggregase activity was very sensitive to mutant subunits that were defective in ATP hydrolysis. Thus, one or two Arg-finger mutant (R561G) subunits, two Walker A mutant (K387A) or sensor-1 mutant (N496K) subunits, or three sensor-2 mutant (R620C) subunits per PARLSkd3 hexamer ablated activity. PARLSkd3 hexamers exhibit some robustness and can buffer the incorporation of a specific number of mutant subunits, i.e., one subunit with a defective Walker-A motif or sensor-1 motif and two subunits with a defective sensor-2 motif. These results reveal that some AAA+ motifs are more important for subunit cooperativity within the hexamer than others. For example, the Arg finger appears to be more critical than the sensor-2 motif. PARLSkd3 hexamers also exhibited robustness against subunits with a defective primary pore loop (Y430A). Thus, PARLSkd3 could tolerate four subunits with the Y430A mutation, indicating that two functional pore loops are required for PARLSkd3 to maintain a grip on substrate during disasaggere. PARLSkd3 differs from Hsp104, which uses a probabilistic mechanism to disassemble disordered luciferase aggregates (DeSantis et al., 2012).

Skd3 is a therapeutic target to inhibit in prostate cancer and Venetoclax-resistant acute myeloid leukemia (Chen et al., 2019; Pudova et al., 2020). Our structures of PARLSkd3 will enable design of small-molecule inhibitors. They are also useful for interpreting disease-linked mutations. SCN-linked mutations cluster within the nucleotide-binding pocket, whereas MGCA7-linked mutations are scattered throughout Skd3. We establish that SCN-linked mutant subunits more sharply inhibit PARLSkd3 ATPase and disaggregase activity than MGCA7-linked subunits. The robustness of PARLSkd3 against inhibition by MGCA7-linked subunits explains why MGCA7-linked mutations are recessive and must be biallelic to cause disease. Moreover, the sharp
inhibition by SCN-linked mutant subunits explains why SCN-linked mutations are dominant negative.

MGCA7 and SCN are caused by loss-of-function Skd3 mutations (Cupo and Shorter, 2020b; Warren et al., 2022). In principle, both diseases could be treated by increasing Skd3 activity. However, due to the mechanistic differences between how MGCA7-linked and SCN-linked subunits affect activity of WT PARLSkd3, different treatment modalities will likely be beneficial for each disease. For treating biallelic MGCA7 mutations, expression of WT Skd3 via adeno-associated viruses (AAVs) is a therapeutic option. Indeed, expression of WT genes via AAVs has yielded therapies for congenital blindness and spinal muscular atrophy (Al-Zaidy et al., 2019; Mendell et al., 2017). Here, the robustness of PARLSkd3 hexamers against MGCA7-linked subunits will enable restoration of PARLSkd3 activity (Figure S6I). By contrast, SCN-linked mutations are dominant negative, and SCN-linked subunits sharply inhibit WT PARLSkd3. Consequently, an AAV strategy to deliver the WT Skd3 gene is likely to be less effective (Figure S6J). We suggest that a therapeutic strategy that reduces or eliminates expression of the mutant Skd3 allele is likely to be more beneficial for SCN. Here, gene editing, specific antisense oligonucleotides, or AAV-delivered siRNA to specifically reduce mutant allele expression could be therapeutic strategies to enable restoration of Skd3 activity.

Limitations of the study

We were unable to resolve a high-resolution structure for the ANK and thus an Alpha -fold model was used. Future studies should solve the atomic structure and dynamics of the ANK. We resolve a PARLSkd3 dodecamer that is formed from the head-to-head contact of two hexamers. We establish that the dodecamer exists in solution, but future studies with endogenous PARLSkd3 ligands will likely be beneficial for each disease. For treating biallelic MGCA7 mutations, expression of WT Skd3 via adeno-associated viruses (AAVs) is a therapeutic option. Indeed, expression of WT genes via AAVs has yielded therapies for congenital blindness and spinal muscular atrophy (Al-Zaidy et al., 2019; Mendell et al., 2017). Here, the robustness of PARLSkd3 hexamers against MGCA7-linked subunits will enable restoration of PARLSkd3 activity (Figure S6I). By contrast, SCN-linked mutations are dominant negative, and SCN-linked subunits sharply inhibit WT PARLSkd3. Consequently, an AAV strategy to deliver the WT Skd3 gene is likely to be less effective (Figure S6J). We suggest that a therapeutic strategy that reduces or eliminates expression of the mutant Skd3 allele is likely to be more beneficial for SCN. Here, gene editing, specific antisense oligonucleotides, or AAV-delivered siRNA to specifically reduce mutant allele expression could be therapeutic strategies to enable restoration of Skd3 activity.

STAR★METHODS

Detailed methods are provided in the online version of this paper and include the following:

- KEY RESOURCES TABLE
- RESOURCE AVAILABILITY
  - Lead contact
  - Materials availability
  - Data and code availability
- EXPERIMENTAL MODEL AND SUBJECT DETAILS
- METHOD DETAILS
  - Multiple sequence alignments
  - Purification of PARLSkd3
  - Purification of Hsp104
  - Purification of Hsc70 and Hdj1
  - Size-exclusion chromatography
  - Size-exclusion chromatography with multicycle light scattering (SEC-MALS)
  - Cryo-EM data collection and processing for PARLSkd3:casein:ATPγS Complex
  - Cryo-EM data collection and processing for PARLSkd3:casein:ATPγS Complex
- QUANTIFICATION AND STATISTICAL ANALYSIS
  - Molecular modeling
  - ATPase assays
  - Luciferase disaggregation and reactivation assays
  - FITC-casein binding assays
  - Modeling heterohexamer ensemble activity
  - Alexa fluor labeling of PARLSkd3
  - Fluorescence resonance energy transfer and subunit mixing
- SUPPLEMENTAL INFORMATION

SUPPLEMENTAL INFORMATION

Supplemental information can be found online at https://doi.org/10.1016/j.celrep.2022.111408.

ACKNOWLEDGMENTS

We thank J. Lin, L. Miller, C. Fare, K. Copley, and Z. Tabassum for feedback and the Johnson Foundation Structural Biology and Biophysics Core for SEC-MALS. Our work was funded by a Blavatnik Family Foundation Fellowship (to R.R.C.), The G Harold and Leila Y Mathers Foundation (to J.S.), and NIH grants T32GM008275 (to R.R.C.), F31AG060872 (to R.R.C.), R01GM099886 (to J.S.), R21AG061784 (to J.S.), and R01GM138690 (to D.R.S.).

AUTHOR CONTRIBUTIONS

Conceptualization, R.R.C., A.N.R., D.R.S., and J.S.; methodology, R.R.C., A.N.R., G.A.B., E.T., E.C., K.G., D.R.S., and J.S.; validation, R.R.C., A.N.R., G.A.B., E.T., and K.G.; formal analysis, R.R.C., A.N.R., E.C., K.G., D.R.S., and J.S.; investigation, R.R.C., A.N.R., G.A.B., E.T., and K.G.; resources, R.R.C., D.R.S., and J.S.; data curation, R.R.C., A.N.R., D.R.S., and J.S.; writing – original draft, R.R.C., A.N.R., D.R.S., and J.S.; writing – review & editing, R.R.C., A.N.R., G.A.B., E.T., E.C., K.G., D.R.S., and J.S.; visualization, R.R.C., A.N.R., D.R.S., and J.S.; supervision, K.G., D.R.S., and J.S.; project administration, D.R.S. and J.S.; funding acquisition, R.R.C., D.R.S., and J.S.

DECLARATIONS OF INTERESTS

J.S. is a consultant for Dewpoint Therapeutics, Confluence Therapeutics, Neumora, and ADRx.

Received: February 25, 2022
Revised: June 2, 2022
Accepted: September 1, 2022
Published: September 27, 2022

SUPPORTING CITATIONS

The following reference appears in the supplemental information: Lee et al. (2003).

REFERENCES

Al-Zaidy, S.A., Kolb, S.J., Lowes, L., Alfano, L.N., Shell, R., Church, K.R., Nagendran, S., Sproule, D.M., Feltner, D.E., Wells, C., et al. (2019). AVXS-101 (onasemnogene abeparvovec) for SMA1: comparative study with a prospective natural history cohort. J. Neuromuscul. Dis. 6, 307–317.
Antonicka, H., Lin, Z.Y., Janer, A., Aaltonen, M.J., Weraarpachai, W., Gingras, A.C., and Shoubridge, E.A. (2020). A high-density human mitochondrial proteome interactome mapping of mitochondrial intermembrane space proteases identifies a novel function for HTRA2. Proteomics 19, e1900139.
Howard, M.K., Sohn, B.S., von Borcke, J., Xu, A., and Jackrel, M.E. (2020). Functional analysis of proposed substrate-binding residues of Hsp104. PLoS One 15, e0230198.
Huang, L., Agrawal, T., Zhu, G., Yu, S., Tao, L., Lin, J., Marmorstein, R., Shorter, J., and Yang, X. (2021). DAIX represents a new type of protein-folding enzyme. Nature 597, 132–137.
Hvung, Y., Poo, P., Rhee, H.W., Udesdi, N.D., Cracan, V., Svininka, T., Carr, S.A., Mootha, V.K., and Ting, A.Y. (2014). Proteomic mapping of the human mitochondrial intermembrane space in live cells via ratiometric APEX tagging. Mol. Cell 55, 332–341.
Imamura, H., Nhat, K.P., Togawa, H., Saito, K., lino, R., Kato-Yamada, Y., Nagai, T., and Noji, H. (2009). Visualization of ATP levels inside single living cells with fluorescence resonance energy transfer-based genetically encoded indicators. Proc. Natl. Acad. Sci. USA 106, 15651–15656.

Jarur-Ampornpan, P., Shen, K., Lam, V.Q., Ali, M., Doniach, S., Jia, T.Z., and Shan, S.O. (2010). ATP-independent reversal of a membrane protein aggregate by a chloroplast SRP subunit. Nat. Struct. Mol. Biol. 17, 596–702.
Jackrel, M.E., DeSantis, M.E., Martinez, B.A., Castellano, L.M., Stewart, R.M., Caldwell, K.A., Caldwell, G.A., and Shorter, J. (2014). Potentiated Hsp104 variants antagonize diverse proteotoxic misfolding events. Cell 156, 170–182.

Jarur-Ampornpan, P., Liang, F.C., Nisthal, A., Nguyen, T.Y., Wang, P., Shen, K., Mayo, S.L., and Shan, S.O. (2013). Mechanism of an ATP-independent protein disaggregation: II. Distinct molecular interactions drive multiple steps during aggregate disassembly. J. Biol. Chem. 288, 13431–13445.
Jumper, J., Evans, R., Pritzel, A., Green, T., Figurnov, M., Ronneberger, O., Tuzun, M., and Larochelle, H. (2016). AlphaFold: protein structure prediction using ensemble deep learning. Nature 536, 338–346.

Karczewski, K.J., Francioni, L.C., Tao, G., Cummings, B.B., Alföldi, J., Wang, Q., Collins, R.L., Laricchia, K.M., Ganna, A., Birmbaum, D.P., et al. (2020). The mutational constraint spectrum quantified from variation in 141,456 humans. Nature 581, 453–444.
Kiyik, A., Gancarz, W., Karakoc-Aydiner, O., Ezen, A., Kiykim, E., Yesil, G., Boztug, K., and Bans, S. (2016). Novel CLPB mutation in a patient with 3-methylglutaconyluria causing severe neurological involvement and congenital neutropenia. Clin. Immunol. 165, 1–3.

Klosowska, A., Chamera, T., and Liberek, K. (2016). Adenosine diphosphate restricts the protein remodeling activity of the Hsp104 chaperone to Hsp70-assisted disaggregation. Elife 5, e1003781.

Koh, A., Binz, H.K., Forrer, P., Stumpf, M.T., Pluckthun, A., and Grutter, M.G. (2003). Designed to be stable: crystal structure of a consensus amyloid protein. Proc. Natl. Acad. Sci. USA 100, 1700–1705.
Lee, S., Sowa, M.E., Watanabe, Y., Sigler, P.B., Chiu, W., Yoshida, M., and Tsai, F.T.-C. (2003). The structure of Cip8: a molecular chaperone that rescues proteins from an aggregated state. Cell 115, 229–240.
Liebschner, D., Afonine, P.V., Baker, D.A., Burkoczi, G., Chen, V.B., Hung, L.W., Jain, S., McCoy, A.J., et al. (2011). Macromolecular structure determination using X-rays, neutrons and electrons: recent developments in PheXen. Acta Crystallogr. D Struct. Biol. 75, 861–877.

Lin, J., Shorter, J., and Lucius, A.L. (2022). AAA+ proteases: one motor, multiple ways to work. Biochem. Soc. Trans. 50, 895–906.

Lo Bianco, C., Shorter, J., Regulier, E., Lashuel, H., Iwatsubo, T., and Tsai, F.T.-C. (2003). The structure of Cip8: a molecular chaperone that rescues proteins from an aggregated state. Cell 115, 229–240.

Lipman, J., Shorter, J., and Regulier, E., Lashuel, H., Iwatsubo, T., Lindquist, S., and Aeberscher, P. (2008). Hsp104 antagonizes alpha-synuclein aggregation and reduces dopaminergic degeneration in a rat model of Parkinson disease. J. Clin. Invest. 118, 3087–3097.

Lopez, K.E., Rizo, A.N., Tse, E., Lin, J., Scull, N.W., Thwin, A.C., Lucius, A.L., Shorter, J., and Southworth, D.R. (2020). Conformational plasticity of the CipA-P AAA+ protease couples protein unfolding and proteolysis. Nat. Struct. Mol. Biol. 27, 408–416.
Mackay, R.G., Helsen, C.W., Tkach, J.M., and Glover, J.R. (2008). The C-terminal extension of Saccharomyces cerevisiae Hsp104 plays a role in oligomer assembly. Biochemistry 47, 1918–1927.

Madeira, F., Park, Y.M., Lee, J., Buso, N., Gur, T., Madhusoodanan, M., Basutkar, P., Tivey, A.R.N., Potter, S.C., Finn, R.D., et al. (2019). The EMBL-EBI search and sequence analysis tools APIs in 2019. Nucleic Acids Res. 47, W636–W641.

McGeoch, A.T., Trakselis, M.A., Laskey, R.A., and Bell, S.D. (2005). Organization of the archeal MCM complex on DNA and implications for the helicase mechanism. Nat. Struct. Mol. Biol. 12, 756–762.

Mendell, J.R., Al-Zaidy, S., Shell, R., Arnold, W.D., Rodino-Klapac, L.R., Prior, T.W., Lowes, L., Alfano, L., Berry, K., Church, K., et al. (2017). Single-dose gene-replacement therapy for spinal muscular atrophy. N. Engl. J. Med. 377, 1713–1722.

Michalska, K., Zhang, K., March, Z.M., Hatzos-Skintges, C., Pentille, G., Bigelow, L., Castellano, L.M., Miles, L.J., Jackrel, M.E., Chuang, E., et al. (2019). Structure of calcarisporiella thermophila Hsp104 disaggregase that antagonizes diverse proteotoxic misfolding events. Structure 27, 449–463.e447.

Moreau, M.J., McGeoch, A.T., Lowe, A.R., Itzhaki, L.S., and Bell, S.D. (2007). ATPase site architecture and helicase mechanism of an archeal MCM. Mol. Cell. 28, 304–314.

Mosavi, L.K., Cammett, T.J., Desorsiers, D.C., and Peng, Z.Y. (2004). The ankyrin repeat as molecular architecture for protein recognition. Protein Sci. 13, 1435–1446.

Mosavi, L.K., Minor, D.L., Jr., and Peng, Z.Y. (2002). Consensus-derived structural determinants of the ankyrin repeat motif. Proc. Natl. Acad. Sci. USA 99, 16029–16034.

Mroz, D., Wyszkowski, H., Szablewski, T., Zawierczak, K., Dutkiewicz, R., Bury, K., Wortmann, S.B., Wevers, R.A., and Ziekiewicz, S. (2020). CLPB (caseinolytic peptidase B homolog), the first mitochondrial protein refolded associated with human disease. Biochim. Biophys. Acta Gen. Subj. 1864, 129512.

Parra, R.G., Espada, R., Verstraete, N., and Ferreiro, D.U. (2015). Structural and energetic characterization of the ankyrin repeat protein family. PLoS Comput. Biol. 11, e1004659.

Perier, F., Radeke, C.M., Raab-Graham, K.F., and Vandenberg, C.A. (1995). Expression of a putative ATPase suppresses the growth defect of a yeast po-
tassium transport mutant: identification of a mammalian member of the Clp/HSP104 family. Gene 152, 157–163.

Pettersen, E.F., Goddard, T.D., Huang, C.C., Couch, G.S., Greenblatt, D.M., Meng, E.C., and Ferrin, T.E. (2004). UCSF Chimera—a visualization system for exploratory research and analysis. J. Comput. Chem. 25, 1605–1612.

Pettersen, E.F., Goddard, T.D., Huang, C.C., Meng, E.C., Couch, G.S., Croll, T.I., Morris, J.H., and Ferrin, T.E. (2021). UCSF ChimeraX: structure visualization for researchers, educators, and developers. Protein Sci. 30, 70–82.

Pronicka, E., Ropacka-Lesiak, M., Trubicka, J., Pajdowska, M., Linke, M., Olszewski, M., Atherton, A., Farrow, E., Miller, N., et al. (2015). CLPB variants asso-
ciated with autosomal-recessive mitochondrial disorder with cataract, neutro-
penia, epilepsy, and methylglutaric aciduria. Am. J. Hum. Genet. 96, 258–265.

Rizo, A.N., Lin, J., Gates, S.N., Tse, E., Bart, S.M., Castellano, L.M., DiMaio, F., Shorter, J., and Southworth, D.R. (2019). Structural basis for substrate grip-
ping and translocation by the ClpB AAA+ disaggregate. Nat. Commun. 10, 2393.

Saita, S., Nolte, H., Fiedler, K.U., Kashkar, H., Venne, A.S., Zahedi, R.P., Kruger, M., and Langer, T. (2017). PARL mediates Smad proteolytic maturation in mitochondria to promote apoptosis. Nat. Cell Biol. 19, 318–328.

Saunders, C., Smith, L., Wibrand, F., Ravn, K., Bros, P., Thiffault, I., Christensen, M., Atherton, A., Farrow, E., Miller, N., et al. (2015). CLPB variants asso-
ciated with autosomal-recessive mitochondrial disorder with cataract, neutro-
penia, epilepsy, and methylglutaric aciduria. Am. J. Hum. Genet. 96, 258–265.

Schirmer, E.C., Quetsch, K., Kowal, A.S., Parsel, D.A., and Lindquist, S. (1998). The ATPase activity of Hsp104, effects of environmental conditions and mutations. J. Biol. Chem. 273, 15546–15552.

Shivhare, D., Ng, J., Tsai, Y.C., and Mueller-Cajar, O. (2019). Probing the rice Rubisco-Rubisco activase interaction via subunit heterooligomerization. Proc. Natl. Acad. Sci. USA 116, 24041–24048.

Shorter, J., and Southworth, D.R. (2019). Spiraling in control: structures and mechanisms of the Hsp104 disaggregate. Cold Spring Harb. Perspect. Biol. 110, 2393.

Skokowa, J., Dale, D.C., Touw, I.P., Zeidler, C., and Welle, K. (2017). Severe congenital neutropenias. Nat. Rev. Dis. Primers 3, 17032.

Spaulding, Z., Thevarajan, I., Schrag, L.G., Zubcovic, L., Zolkiewska, A., and Zolkiewski, M. (2022). Human mitochondrial AAA+ ATPase SKD3/CLPB as-
sembles into nucleotide-stabilized dodecamers. Biochem. Biophys. Res. Commun. 602, 21–26.

Spinazzi, M., Radaelli, E., Horre, K., Arranz, A.M., Gounko, N.V., Agostinis, P., Maia, T.M., Impens, F., Morais, V.A., Lopez-Lluch, G., et al. (2019). PARL defi-
ciency in mouse causes Complex III defects, coenzyme Q depletion, and Leigh-like syndrome. Proc. Natl. Acad. Sci. USA 116, 277–286.

Sweeney, E.A., Jackrel, M.E., Go, M.S., Sochor, M.A., Razzo, B.M., De-
santis, M.E., Gupta, K., and Shorter, J. (2015). The Hsp104 N-terminal domain enables disaggregate plasticity and potentiation. Mol. Cell 57, 836–849.

The UniProt Consortium (2021). UniProt: the universal protein knowledgebase in 2021. Nucleic Acids Res. 49, D480–D489.

Thevarajan, I., Zolkiewski, M., and Zolkiewska, A. (2020). Human CLPB homologs form ATP-dependent complexes in the mitochondrial intermembrane space. Int. J. Biochem. Cell Biol. 127, 105841.

Varadi, M., Anyango, S., Deshpande, M., Nair, S., Natassia, C., Yordanova, G., Yuan, D., Stroe, O., Wood, G., Laydon, A., et al. (2022). AlphaFold Protein Structure Database: massively expanding the structural coverage of protein-sequence space with high-accuracy models. Nucleic Acids Res. 50, D439–D444.

Vieux, E.F., Wohlever, M.L., Chen, J.Z., Sauer, R.T., and Baker, T.A. (2013). Distinct quaternary structures of the AAA+ Lon protease control substrate degradation. Proc. Natl. Acad. Sci. USA 110, E2002–E2008.

Wang, R.Y., Song, Y., Barad, B.A., Cheng, Y., Fraser, J.S., and DiMaio, F. (2016). Automated structure refinement of macromolecular assemblies from cryo-EM maps using Rosetta. Elife 5, e17219.
Warren, J.T., Cupo, R.R., Wattanasirakul, P., Spencer, D.H., Locke, A.E., Makaryan, V., Bolyard, A.A., Kelley, M.L., Kingston, N.L., Shorter, J., et al. (2022). Heterozygous variants of CLPB are a cause of severe congenital neutropenia. Blood 139, 779–791.

Waterhouse, A., Bertoni, M., Bienert, S., Studer, G., Tauriello, G., Gumieny, R., Heer, F.T., de Beer, T.A.P., Rempfer, C., Bordoli, L., et al. (2018). SWISS-MODEL: homology modelling of protein structures and complexes. Nucleic Acids Res. 46, W296–W303.

Weaver, C.L., Duran, E.C., Mack, K.L., Lin, J., Jackrel, M.E., Sweeny, E.A., Shorter, J., and Lucius, A.L. (2017). Avidity for polypeptide binding by nucleotide-bound Hsp104 structures. Biochemistry 56, 2071–2075.

Werbeck, N.D., Schlee, S., and Reinstein, J. (2008). Coupling and dynamics of subunits in the hexameric AAA+ chaperone ClpB. J. Mol. Biol. 378, 178–190.

Wortmann, S.B., Zietkiewicz, S., Kousi, M., Szklarczyk, R., Haack, T.B., Gersting, S.W., Muntau, A.C., Rakovic, A., Renkema, G.H., Rodenburg, R.J., et al. (2019). CLPB mutations cause 3-methylglutaconic aciduria, progressive brain atrophy, intellectual disability, congenital neutropenia, cataracts, movement disorder. Am. J. Hum. Genet. 96, 245–257.

Wortmann, S.B., Zietkiewicz, S., Guerrero-Castillo, S., Feichtinger, R.G., Wagner, M., Russell, J., Eltaway, C., Mroz, D., Wyszkowski, H., Weis, D., et al. (2021). Neutropenia and intellectual disability are hallmarks of biallelic and de novo CLPB deficiency. Genet. Med. 23, 1705–1714.

Wu, D., Liu, Y., Dai, Y., Wang, G., Lu, G., Chen, Y., Li, N., Lin, J., and Gao, N. (2022). Structure and mechanism of a mitochondrial AAA+ disaggregate CLBP. Preprint at bioRxiv. https://doi.org/10.1101/2022.03.10.483744.

Yoo, H., Bard, J.A.M., Pilipenko, E.V., and Drummond, D.A. (2022). Chaperones directly and efficiently disperse stress-triggered biomolecular condensates. Mol. Cell 82, 741–755.e711.

Zheng, S.Q., Palovcak, E., Armache, J.P., Verba, K.A., Cheng, Y., and Agard, D.A. (2017). MotionCor2: anisotropic correction of beam-induced motion for improved cryo-electron microscopy. Nat. Methods 14, 331–332.

Zhu, G., Harischandra, D.S., Ghaisas, S., Zhang, P., Prall, W., Huang, L., Maghames, C., Guo, L., Luna, E., Mack, K.L., et al. (2020). TRIM11 prevents and reverses protein aggregation and rescues a mouse model of Parkinson’s disease. Cell Rep. 33, 108418.
## STAR METHODS

### KEY RESOURCES TABLE

| REAGENT or RESOURCE                        | SOURCE                     | IDENTIFIER        |
|--------------------------------------------|----------------------------|-------------------|
| **Bacterial and virus strains**            |                            |                   |
| E. coli BL21-CodonPlus (DE3) RIL competent cells | Agilent                    | Cat#230245        |
| **Chemicals, peptides, and recombinant proteins** |                            |                   |
| Creatine phosphate                         | Roche                      | Cat#10621722001   |
| Adenosine-5’-Diphosphate Monosodium Salt (ADP) | MP Biomedicals              | Cat#150260        |
| Adenylyl-imidodiphosphate (AMP-PNP)        | Roche                      | Cat#10102547001   |
| Adenosine 5’-triphosphate disodium salt hydrate (ATP) | Sigma-Aldrich              | Cat#A3377         |
| Adenosine-5’-o-(3-thio-triphosphate) (ATP₃S) | Roche                      | Cat#10102342001   |
| cOmplete, Mini, EDTA-free Protease Inhibitor Cocktail | Sigma-Aldrich              | Cat#4693159001    |
| Pepstatin A, microbial, ≥90% (HPLC)        | Sigma-Aldrich              | Cat#P5318         |
| Alexa Fluor™ 488 NHS Ester (Succinimidyl Ester) | ThermoFisher Scientific    | Cat#A20000        |
| Alexa Fluor™ 594 NHS Ester (Succinimidyl Ester) | ThermoFisher Scientific    | Cat#A20004        |
| Casein fluorescein isothiocyanate from bovine milk (FITC-Casein) | Sigma-Aldrich              | Cat#C0528         |
| Creatine kinase                            | Roche                      | Cat#10127566001   |
| Firefly luciferase                          | Sigma-Aldrich              | Cat#L9506         |
| Lysozyme                                   | Sigma-Aldrich              | Cat#L6876         |
| His-TEV protease                           | (Cupo and Shorter, 2020a, b) | N/A               |
| Hdj1                                       | (Cupo and Shorter, 2020b; Michalska et al., 2019) | N/A               |
| Hsc70                                      | (Cupo and Shorter, 2020b; Michalska et al., 2019) | N/A               |
| Hsp104                                     | (DeSantis et al., 2012; Jackrel et al., 2014) | N/A               |
| PARLSkd3                                    | (Cupo and Shorter, 2020a, b) | N/A               |
| PARLSkd3Δ431G                               | This paper                 | N/A               |
| PARLSkd3Δ447A                               | This paper                 | N/A               |
| PARLSkd3Δ49D                                | (Cupo and Shorter, 2020b)  | N/A               |
| PARLSkd3Δ1-2                                | This paper                 | N/A               |
| PARLSkd3Δ1L                                 | This paper                 | N/A               |
| PARLSkd3Δ2-4                                | This paper                 | N/A               |
| PARLSkd3ΔL507-I534                          | This paper                 | N/A               |
| PARLSkd3ΔL660-I707                          | This paper                 | N/A               |
| PARLSkd3ΔK387A                              | (Cupo and Shorter, 2020b)  | N/A               |
| PARLSkd3ΔY430A                              | (Cupo and Shorter, 2020b)  | N/A               |
| PARLSkd3ΔR408G                              | (Warren et al., 2022)      | N/A               |
| PARLSkd3ΔR475Q                              | (Cupo and Shorter, 2020b)  | N/A               |
| PARLSkd3ΔA591V                              | (Cupo and Shorter, 2020b)  | N/A               |
| PARLSkd3ΔQ496K                              | (Warren et al., 2022)      | N/A               |
| PARLSkd3ΔR610G                              | (Warren et al., 2022)      | N/A               |
| PARLSkd3ΔR622-C                             | (Warren et al., 2022)      | N/A               |
| **Critical commercial assays**              |                            |                   |
| ATPase Activity Kit (Colorimetric)          | Innova Biosciences         | Cat#601-0120      |
| Luciferase Assay Reagent                    | Promega                    | Cat#E1483         |
| **Deposited data**                          |                            |                   |
| EMDB: 26121                                 | This paper                 | N/A               |
| EMDB: 26122                                 | This paper                 | N/A               |

(Continued on next page)
Continued

**REAGENT or RESOURCE** | **SOURCE** | **IDENTIFIER**
--- | --- | ---
PDB: 7TTR | This paper | N/A
PDB: 7TTS | This paper | N/A

**Recombinant DNA**

| REAGENT or RESOURCE | SOURCE | IDENTIFIER |
|---------------------|--------|------------|
pHis-TEV | (Cupo and Shorter, 2020a, b) | N/A |
pESUMO-Hdj1 | (Cupo and Shorter, 2020b; Michalska et al., 2019) | N/A |
pESUMO-Hsc70 | (Cupo and Shorter, 2020b; Michalska et al., 2019) | N/A |
pNOTAG-Hsp104 | (DeSantis et al., 2012; Jackrel et al., 2014) | N/A |
pMAL-C2-TEV-Parlskd3 | (Cupo and Shorter, 2020a, b) | N/A |
pMAL-C2-TEV-Parlskd3<sup>V431G</sup> | This paper | N/A |
pMAL-C2-TEV-Parlskd3<sup>R417A</sup> | This paper | N/A |
pMAL-C2-TEV-Parlskd3<sup>NBD</sup> | (Cupo and Shorter, 2020b) | N/A |
pMAL-C2-TEV-Parlskd3<sup>Δ1,2</sup> | This paper | N/A |
pMAL-C2-TEV-Parlskd3<sup>ΔL</sup> | This paper | N/A |
pMAL-C2-TEV-Parlskd3<sup>Δ3,4</sup> | This paper | N/A |
pMAL-C2-TEV-Parlskd3<sup>ΔL507-6534</sup> | This paper | N/A |
pMAL-C2-TEV-Parlskd3<sup>ΔL660-7767</sup> | This paper | N/A |
pMAL-C2-TEV-Parlskd3<sup>K387A</sup> | (Cupo and Shorter, 2020b) | N/A |
pMAL-C2-TEV-Parlskd3<sup>Y430A</sup> | (Cupo and Shorter, 2020b) | N/A |
pMAL-C2-TEV-Parlskd3<sup>R408G</sup> | (Warren et al., 2022) | N/A |
pMAL-C2-TEV-Parlskd3<sup>R475Q</sup> | (Cupo and Shorter, 2020b) | N/A |
pMAL-C2-TEV-Parlskd3<sup>R408G</sup> | (Warren et al., 2022) | N/A |
pMAL-C2-TEV-Parlskd3<sup>R475Q</sup> | (Cupo and Shorter, 2020b) | N/A |
pMAL-C2-TEV-Parlskd3<sup>N496K</sup> | (Warren et al., 2022) | N/A |
pMAL-C2-TEV-Parlskd3<sup>R561G</sup> | (Warren et al., 2022) | N/A |
pMAL-C2-TEV-Parlskd3<sup>R561G</sup> | (Warren et al., 2022) | N/A |

**Software and algorithms**

| SOFTWARE | SOURCE | IDENTIFIER |
|----------|--------|------------|
| BOXSHADE | Github | [https://github.com/mbaron42/pyBoxshade](https://github.com/mbaron42/pyBoxshade) |
| Clustal Omega | (Madeira et al., 2019) | N/A |
| Prism 8 | GraphPad | N/A |
| ASTRA, version 8.0 | Wyatt Technology | N/A |
| cryoSPARC version 2.0–3.3.2 | Structura Biotechnology Inc. | N/A |
| Chimera | (Pettersen et al., 2004) | N/A |
| ChimeraX version 1.2.5–1.3 | (Pettersen et al., 2021) | N/A |
| ISOLDE | (Croll, 2018) | N/A |
| cisTEM | (Grant et al., 2018) | N/A |
| Phenix (Phenix Real Space Refine) | (Liebschner et al., 2019) | N/A |
| Coot | (Emsley et al., 2010) | N/A |
| Rosetta (2020.08 Release) | (Wang et al., 2016) | N/A |
| AlphaFold | (Jumper et al., 2021; Varadi et al., 2022) | N/A |

**RESOURCE AVAILABILITY**

**Lead contact**

Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, James Shorter (jshorter@pennmedicine.upenn.edu).

**Materials availability**

Plasmids newly generated in this study will be made readily available to the scientific community. We will honor requests in a timely fashion. Material transfers will be made with no more restrictive terms than in the Simple Letter Agreement or the Uniform Biological Materials Transfer Agreement and without reach through requirements.
Homo sapiens alignment. Alignment image was generated via BoxShade tool as described previously (Cupo and Shorter, 2020b). The linker region of the ankyrin repeats was aligned manually to the Clustal Omega

Escherichia coli Hsp104, PARLSkd3 and variants were purified as previously described (Cupo and Shorter, 2020a, b). In short, PARLSkd3 and variants were expressed with an N-terminal His-SUMO tag in BL21 (DE3) RIL cells (Agilent). Cells were lysed via sonication in lysis buffer (40 mM HEPES-KOH pH = 7.5, 750 mM KCl, 10 mM MgCl2, 10% glycerol, 20 mM imidazole, 1 mM ATP, and 2 mM DTT). The protein was run over a size exclusion column (GE Healthcare HiPrep 26/60 Sephacryl S-300 HR) in sizing buffer (50 mM Tris-HCl pH = 8.0, 500 mM KCl, 10% glycerol, 20 mM imidazole, 5 mM MgCl2, and 1 mM DTT). Peak fractions were collected, concentrated to ~5 mg/mL, supplemented with 5 mM ATP, and snap frozen. Protein purity was determined to be >95% by SDS-PAGE and Coomassie staining.

Purification of Hsp104

Hsp104 was purified as previously described (DeSantis et al., 2012). In short, Hsp104 was expressed in BL21 (DE3) RIL cells, lysed via sonication in lysis buffer (50 mM Tris-HCl pH = 8.0, 10 mM MgCl2, 2.5% glycerol, 2 mM β-mercaptoethanol, 2.5 μM PepstatinA, and cOmplete Protease Inhibitor Cocktail [one tablet/250 mL, Millipore Sigma]), Lysates were centrifuged at 30,597xg and 4°C for 20 min and the supernatant was applied to amylose resin (NEB). The column was washed with 15 column volumes (CV) of wash buffer (WB: 40 mM HEPES-KOH pH = 7.4, 500 mM KCl, 20% [w/v] glycerol, 5 mM ATP, 10 mM MgCl2, 2 mM β-mercaptoethanol, 2.5 μM PepstatinA, and cOmplete Protease Inhibitor Cocktail [one tablet/250 mL, Millipore Sigma]). The protein was run over a size exclusion column (GE Healthcare HiPrep 26/60 Sephacyr S-300 HR) in sizing buffer (50 mM Tris-HCl pH = 8.0, 500 mM KCl, 10% glycerol, 1 mM ATP, 10 mM MgCl2, and 1 mM DTT). Peak fractions were collected, concentrated to ~5 mg/mL, supplemented with 5 mM ATP, and snap frozen. Protein purity was determined to be >95% by SDS-PAGE and Coomassie staining.

Purification of Hsc70 and Hdj1

Hsc70 and Hdj1 were purified as previously described (Michalska et al., 2019). Hsc70 and Hdj1 were expressed in BL21 (DE3) RIL cells with an N-terminal His-SUMO tag. Cells were lysed via sonication into lysis buffer (50 mM HEPES-KOH pH = 7.5, 750 mM KCl, 5 mM MgCl2, 10% glycerol, 20 mM imidazole, 2 mM β-mercaptoethanol, 5 μM peptatin A, and cOmplete Protease Inhibitor Cocktail [one mini EDTA-free tablet/50 mL, Millipore Sigma]). Lysates were centrifuged at 30,597xg and 4°C for 20 min. The supernatant was bound to Ni-NTA Agarose resin (Qiagen), washed with 10 CV of wash buffer (50 mM HEPES-KOH pH = 7.5, 750 mM KCl, 10 mM MgCl2, 10% glycerol, 20 mM imidazole, 1 mM ATP, and 2 mM β-mercaptoethanol), and eluted with 2 CV of elution buffer (wash buffer supplemented with 300 mM imidazole). The protein was further purified via loading onto a 5 mL Histrap HP column (GE Healthcare) and cOmplete Protease Inhibitor Cocktail [1 full size tablet/50 mL, Millipore Sigma]) at 4°C, 3 CV of WB supplemented with 20 mM ATP at 25°C for 30 min, and an additional 15 CV of WB at 4°C. The protein was then washed with ~8 CV of elution buffer (EB: 50 mM Tris-HCl pH = 8.0, 300 mM KCl, 10% glycerol, 5 mM ATP, 10 mM MgCl2, and 2 mM β-mercaptoethanol) and eluted via TEV protease cleavage at 34°C. The protein was run over a size exclusion column (GE Healthcare HiPrep 26/60 Sephacyr S-300 HR) in sizing buffer (50 mM Tris-HCl pH = 8.0, 500 mM KCl, 10% glycerol, 1 mM ATP, 10 mM MgCl2, and 1 mM DTT). Purification of PARLSkd3

PARLSkd3 and variants were purified as previously described (Cupo and Shorter, 2020a, b). In short, PARLSkd3 and variants were expressed with an N-terminal MBP-tag in BL21 (DE3) RIL cells (Agilent). Cells were lysed via sonication in lysis buffer (40 mM HEPES-KOH pH = 7.4, 500 mM KCl, 20% [w/v] glycerol, 5 mM ATP, 10 mM MgCl2, 2 mM β-mercaptoethanol, 2.5 μM PepstatinA, and cOmplete Protease Inhibitor Cocktail [one tablet/250 mL, Millipore Sigma]). Lysates were centrifuged at 30,597xg and 4°C for 20 min and the supernatant was applied to amylose resin (NEB). The column was washed with 15 column volumes (CV) of wash buffer (WB: 40 mM HEPES-KOH pH = 7.4, 500 mM KCl, 20% [w/v] glycerol, 5 mM ATP, 10 mM MgCl2, 2 mM β-mercaptoethanol, 2.5 μM PepstatinA, and cOmplete Protease Inhibitor Cocktail [one full size tablet/50 mL, Millipore Sigma]) at 4°C, 3 CV of WB supplemented with 20 mM ATP at 25°C for 30 min, and an additional 15 CV of WB at 4°C. The protein was then washed with ~8 CV of elution buffer (EB: 50 mM Tris-HCl pH = 8.0, 300 mM KCl, 10% glycerol, 5 mM ATP, 10 mM MgCl2, and 2 mM β-mercaptoethanol) and eluted via TEV protease cleavage at 34°C. The protein was run over a size exclusion column (GE Healthcare HiPrep 26/60 Sephacyr S-300 HR) in sizing buffer (50 mM Tris-HCl pH = 8.0, 500 mM KCl, 10% glycerol, 1 mM ATP, 10 mM MgCl2, and 1 mM DTT). Peak fractions were collected, concentrated to ~5 mg/mL, supplemented with 5 mM ATP, and snap frozen. Protein purity was determined to be >95% by SDS-PAGE and Coomassie staining.

Data and code availability

- **PARLSkd3:casein:ATP** cryo-EM maps and atomic coordinates have been deposited in the EMDB and PDB with accession codes EMDB: 26121 (State 1), EMDB: 26122 (State 1 filtered), PDB: 7TTR (State 1, AAA + only), and PDB: 7TTS (State 1, Full Model). The original/source data in the paper are available from the lead contact upon reasonable request.
- This paper did not generate code.
- Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request.

**EXPERIMENTAL MODEL AND SUBJECT DETAILS**

*Escherichia coli* BL21-CodonPlus (DE3)-RIL competent cells (Genotype: B F–ompT hsdS(rB – mB –) dcm + Tetr gal I (DE3) endA Hte [argU ileY leuW Camr] (Agilent, Cat#230245) were used to express recombinants for purification.

**METHOD DETAILS**

Multiple sequence alignments

NBD sequences were acquired via UniProtKB for *Homo sapiens* Skd3, *Escherichia coli* ClpA, *Escherichia coli* ClpB, *Staphylococcus aureus* ClpC, *Escherichia coli* ClpX, *Saccharomyces cerevisiae* Hsp78, *Arabidopsis thaliana* Hsp101, *Saccharomyces cerevisiae* Hsp104, *Escherichia coli* RuvB, and *Pseudomonas aeruginosa* ClpG. Ankyrin-repeat sequences were acquired via UniProtKB for *Homo sapiens* Skd3. Consensus ankyrin repeat was derived from Mosavi, et al. (Mosavi et al., 2002). Compiled sequences were aligned via Clustal Omega (Madeira et al., 2019). The linker region of the ankyrin repeats was aligned manually to the Clustal Omega alignment. Alignment image was generated via BoxShade tool as described previously (Cupo and Shorter, 2020b).
and pooling the untagged elution. The protein was pooled and concentrated, and then purified further via Resource Q ion-exchange chromatography. The elution was pooled, concentrated, and snap frozen. Protein purity was determined to be >95% via SDS-PAGE and Coomassie staining.

**Size-exclusion chromatography**

All size-exclusion chromatography experiments were run on a Superose 6 Increase 3.2/300 (Cytiva) column pre-equilibrated in buffer containing: 40 mM HEPES (pH = 8.0), 40 mM KCl, 10 MgCl₂, and 1 mM DTT. To form a substrate-bound complex, PARLSkd3 (20 μM) was incubated with FITC-casein (55 μM) (#C0528; Sigma) in the presence of nucleotide (ATP₇S, ATP, ADP, or AMP-PNP) (5 mM) for 15 min at room temperature. For experiments without FITC-casein, PARLSkd3 (20 μM) and nucleotide (ATP₇S, ATP, ADP, or AMP-PNP) (5 mM) were incubated for 15 min at room temperature. After the incubation period, the samples were spin-filtered before injecting on column.

**Size-exclusion chromatography with multangle light scattering (SEC-MALS)**

Experiments were conducted at the Johnson Foundation Structural Biology and Biophysics Core at the Perelman School of Medicine (Philadelphia, PA). The SEC experiments were performed using 100 μL injections (125 μM PARLSkd3) with a Superose 6 Increase 10/300 GL column (GE Life Sciences) at 0.5 mL/min at room temperature. The column was equilibrated with 20 mM Tris-HCl (pH = 8.0), 150 mM KCl, and 10 mM MgCl₂ and 1 mM DTT at 25°C. Absolute molecular weights were determined by MALSS. The scattered light intensity of the column eluent was recorded at 18 different angles using a DAWN-HELEOS MALS detector (Wyatt Technology Corporation) operating at 658 nm after calibration with the monomer fraction of Type V BSA (Sigma). The protein concentration of the eluent was determined using an in-line Optilab T-rex interferometric refractometer (Wyatt Technology Corporation). The weight-averaged molecular weight of species within defined chromatographic peaks was calculated using the software ASTRA, version 8.0 (Wyatt Technology Corporation), by construction of Debye plots [(KC/R sin²(θ/2)] at 1/S data intervals. The weight-averaged molecular weight was then calculated at each point of the chromatographic trace from the Debye plot intercept, and an overall average molecular weight was calculated by averaging across the peak.

**Cryo-EM data collection and processing for PARLSkd3:casein:ATP₇S Complex**

To form a substrate-bound complex, PARLSkd3 (55 μM) was incubated with FITC-casein (55 μM) (#C0528; Sigma) in the presence of ATP₇S (5 mM) in buffer containing: 40 mM HEPES (pH = 8.0), 40 mM KCl, 10 MgCl₂, 1 mM DTT. After incubating for 15 min at room temperature, the sample was applied to a Superose 6 Increase 3.2/300 column (GE Healthcare) for size exclusion chromatography (SEC) analysis. The fraction corresponding to the largest molecular weight complex from SEC of PARLSkd3 and FITC-casein (Figure 1B) was isolated and incubated with 1 mM ATP₇S. Before freezing, proper dilutions were made to a final concentration of ~7 mg/mL and a 3.0 μL drop was applied to glow discharged holey carbon (R 1.2/1.3; Quantifoil), then blotted for 3 s at 4°C and 100% humidity with a blot force of 1, followed by an additional 3.0μL drop. The sample was then blotted again for 2 s with a blot force of 0 with Whatman No. 1 filter paper before being plunge frozen in liquid ethane using a Vitrobot (Thermo Fischer Scientific).

The sample was then imaged on a Titan Krios TEM (Thermo Fischer Scientific) operated at 300 kV and equipped with a Gatan BioQuantum imaging energy filter using a 20eV zero loss energy slit (Gatan Inc.). Movies were acquired in super-resolution mode on a K3 direct electron detector (Gatan Inc.) at a nominal magnification of 105,000X corresponding to a physical pixel size of 0.417 Å/pixel. A defocus range of 0.8–1.2 μm was used with a total exposure time of 2 s fractionated into 0.2s subframes for a total dose of 68 e⁻/Å² at a dose rate of 25 e⁻/pixel/s. Movies were subsequently corrected for drift using MotionCor2 (Zheng et al., 2017) and were Fourier cropped by a factor of 2 to a final pixel size of 0.834 Å/pixel.

A total of ~30,000 micrographs were collected over multiple datasets. Micrograph quality was assessed and poor micrographs, including those above the resolution cutoff of ~5Å, were discarded. The individual datasets were processed separately to ensure data quality before combining them all together for further processing. Data processing was performed in cryoSPARC v3.2 (Punjani et al., 2017). For particle picking, blob picker was set to 180 Å-200 Å for minimum and maximum particle diameter and the particles picked were inspected before extracting particles. 2D classification was performed to remove contamination and junk particles and good classes were selected which left ~900,000 remaining particles. Four different ab-initio models were reconstructed which were then used in 3D classification.

Heterogeneous refinement was performed with different classes, which resulted in 3 distinct classes: hexamer, Class 1 (41%, ~358K particles); heptamer, Class 3 (19%, ~167K particles); and dodecamer, Class 2 (15%, ~130K particles); Other, Class 4 (24%, ~210K particles) (Figure S1F). Each of the classes underwent homogeneous refinement which resulted in resolutions of 9Å for the dodecamer, 7 Å for the heptamer and 3.2Å for the hexamer. To improve the resolution, non-uniform refinement was completed on both the dodecamer and hexamer to improve the resolutions to 7.2Å and 2.9Å respectively (Figure S2B). Both classes underwent local CTF refinement which did not result in an improvement in resolution.

**Cryo-EM data collection and processing for PARLSkd3¹-²:casein:ATP₇S Complex**

To form a substrate-bound complex, PARLSkd3¹-² (40 μM) was incubated with FITC-casein (40 μM) (#C0528; Sigma) in the presence of ATP₇S (5 mM) in buffer containing: 40 mM HEPES (pH = 8.0), 40 mM KCl, 10 MgCl₂, 1 mM DTT. After incubating for 15 min at room temperature, grids were prepared. For grid freezing, a 3.0 μL drop was applied to glow discharged holey carbon (R 1.2/1.3;
Quantifoil), then blotted for 3 s at 4 °C and 100% humidity with a blot force of 1 followed by an additional 3.0 µL drop. The sample was then blotted again for 2 s with a blot force of 0 with Whatman No. 1 filter paper before being plunge frozen in liquid ethane using a Vitrobot (Thermo Fisher Scientific).

The sample was then imaged on a Glacios TEM (Thermo Fisher Scientific) operated at 200 keV (Gatan Inc.). Movies were acquired in super-resolution mode on a K2 direct electron detector (Gatan Inc.) at a nominal magnification of 45,000X corresponding to a physical pixel size of 0.486 Å/pixel. A defocus range of 1.0–2.0 μm was used with a total exposure time of 6 s fractionated into 0.065 subframes for a total dose of 55.8 e-/Å² at a dose rate of 8 e-/pixel/s. Movies were subsequently corrected for drift using MotionCor2 (Zheng et al., 2017) and were Fourier cropped by a factor of 2 to a final pixel size of 0.972 Å/pixel.

A total of ~15,000 micrographs were collected over multiple datasets. The individual datasets were processed separately to ensure data quality before combining them all together for further processing. Micrograph quality was assessed and poor micrographs, including those above the resolution cutoff of ~5 Å, were discarded. Data processing was performed in cryoSPARC v3.2 (Punjani et al., 2017). For particle picking, blob picker was set to 180 Å-200 Å for minimum and maximum particle diameter and the particles picked were inspected before extracting particles. 2D classification was performed in two rounds to remove contamination and junk particles and good classes were selected which left ~700,000 remaining particles. The results from a previous 3D classification were used as the starting models for 3D classification.

Heterogeneous refinement was performed with 4 different classes, which resulted in 3 distinct classes: dodecamer, Class 1 (24%, ~165K particles); bent dodecamer, Class 2 (30%, ~203K particles); trimer, Class 3 (32%, ~213K particles); and other, Class 4 (14%, ~95K particles) (Figure S3I). Each of the classes underwent homogeneous refinement which resulted in resolutions of 8 Å for the dodecamer, 7 Å for the bent dodecamer and 8 Å for the trimer (Figure S3J).

**Molecular modeling**

An initial model for PARLSkd3 was generated in SWISS-MODEL (Waterhouse et al., 2018) and was docked into the EM map using the UCSF chimera’s function fit in map (Petterson et al., 2004). The initial model lacked the ANK so the SWISS-MODEL generated model was combined with the Alpha-fold prediction of the ANK taken from the AlphaFold Protein Structure Database. Initial refinement was performed using RosettaRelax in cartesian space to generate 30 different models. The model/model quality for each model generated was examined in Chimera (Petterson et al., 2004) and the lowest energy minimized model was used moving forward. Various outliers and poorly fit density were manually fixed using ISOLDE (Croll, 2018) in ChimeraX (Petterson et al., 2021). To fix most of the outliers another round of RosettaRelax in cartesian space was performed followed by iterative rounds of refinement in Phenix Real Space Refine (Liebschner et al., 2019). The model from Phenix Real Space refinement was taken and used in a final round of Rosetta FastRelax in tensor space to remove the various clashes that were introduced during Phenix refinement.

**ATPase assays**

Hsp104, PARLSkd3, and PARLSkd3 variants (0.25 μM monomer) were incubated with ATP (1 mM) (Innova Biosciences) at 37 °C for 5 min in luciferase reactivation buffer (LRB; 25 mM HEPES-KOH [pH = 8.0], 150 mM KAOc, 10 mM MgAOc, 10 mM DTT). ATPase activity was assessed via inorganic phosphate release with a malachite green detection assay (Expedeon) and measured in Nunc 96 Well Optical plates on a Tecan Infinite M1000 plate reader. Background hydrolysis was measured at time zero and subtracted.

**Luciferase disaggregation and reactivation assays**

Firefly luciferase was then rapidly diluted 100-fold into ice-cold LRB, snap frozen, and stored at −80 °C until use. Hsp104 (1 μM monomer) was incubated with 50 nM aggregated firefly luciferase in the presence or absence of Hsc70 and Hdj2 (0.167 μM each) in LRB plus 5 mM ATP plus an ATP regeneration system (ARS; 1 mM creatine phosphate and 0.25 mM hexameric) of PARLSkd3 with 2 mM of the indicated nucleotide for 10 min at 25 °C. For the ATP condition, an ATP regeneration system (5 mM creatine phosphate and 0.125 μM β-mercaptoethanol) was used. To assess FITC-casein binding, FITC-casein (60 nM, Sigma) was incubated with increasing concentrations (0–2.5 μM) in LRB (pH = 7.4) with 8 M urea at 30 °C for 90 min (unless otherwise indicated). PARLSkd3 and variants (1 μM monomer, unless otherwise indicated) were incubated with 50 nM aggregated firefly luciferase in LRB plus 5 mM ATP plus ARS at 37 °C for 90 min (unless otherwise indicated). Nucleotide-inhibitor assays for PARLSkd3 disaggregation activity were tested in the presence of ATP (Sigma), ATPγS (Roche), or ADP (MP Biomedicals) for 30 min at 37 °C without ARS. IC50 curves for ADP and ATPγS were fitted using GraphPad Prism with a variable slope (four parameters) least squares fit. Recovered luminescence was monitored in Nunc 96 Well Optical plates using a Tecan Infinite M1000 plate reader (Cupo and Shorter, 2020b; DeSantis et al., 2012). ATPase kinetics for PARLSkd3 were calculated using GraphPad Prism with a Michaelis-Menten least squares fit which was subsequently used to derive Km and Vmax.

**FITC-casein binding assays**

Fluorescence polarization was performed essentially as described previously (Rizo et al., 2019). PARLSkd3 was exchanged into 40 mM HEPES-KOH pH 8.0, 20 mM MgCl2, 150 mM KCl, 10% Glycerol (v/v), 2 mM β-mercaptoethanol. To assess FITC-casein binding, FITC-casein (60 nM, Sigma) was incubated with increasing concentrations (0–2.5 μM hexameric) of PARLSkd3 with 2 μM of the indicated nucleotide for 10 min at 25 °C. For the ATP condition, an ATP regeneration system (5 mM creatine phosphate and 0.125 μM β-mercaptoethanol) was used.
creatinine kinase) was included to maintain 2 mM ATP. Fluorescence polarization was measured (excitation 470 nm, emission 520 nm) using a Tecan Infinite M1000 plate reader. The binding isotherms were analyzed using Prism.

**Modeling heterohexamer ensemble activity**

The binomial distribution was used to model the activity of various heterohexamer ensembles (DeSantis et al., 2012; Werbeck et al., 2008):

\[
P(k) = \binom{n}{k} p^k (1 - p)^{n-k}
\]

Where: \(P(k)\) is the probability of a hexamer containing \(k\) mutant subunits, \(n\) is total number of subunits (which for a hexamer, \(n = 6\)), and \(p\) is the probability that a mutant subunit is incorporated. FRET subunit mixing experiments demonstrated that mutant and WT subunits have a similar probability of being incorporated into a hexamer (Figures S5D, 6A and 6B). Thus, \(p\) is calculated as the molar ratio of mutant and WT protein present:

\[
p = \frac{\text{Skd3mutant}}{\text{Skd3WT}}
\]

Therefore, for any specified concentration of mutant protein, the probability distribution of \(\text{PARLSkd3}\) hexamers containing zero, one, two, three, four, five, or six mutant subunits can be derived (Figure 6A). Activity versus \(p\) plots (Figure 6B) can then be generated assuming each WT subunit makes an equal contribution to the total activity (one-sixth per subunit). Consequently, if subunits within the hexamer operate independently then activity should decline linearly upon incorporation of mutant subunits. Conversely, if subunit activity is coupled then the incorporation of a specific number of subunits will be sufficient to abolish activity. In our model, zero activity is assigned to hexamers that exceed the specific threshold number of mutant subunits. In this way, we generate activity versus \(p\) plots by assuming that 1 or more, 2 or more, 3 or more, 4 or more, or 5 or more mutant subunits are required to eliminate activity. This formula can be expressed as:

\[
\text{Activity} (\%) = 100 \times \left[ (P_0 A_0) + (P_1 A_1) + (P_2 A_2) + (P_3 A_3) + (P_4 A_4) + (P_5 A_5) + (P_6 A_6) \right]
\]

Where: \(P(k)\) is the probability of hexamer containing \(k\) mutant subunits derived above and \(A(k)\) is the relative assigned contribution to activity of a hexamer containing \(k\) mutant subunits.

**Alexa fluor labeling of \(\text{PARLSkd3}\)**

For Förster resonance energy transfer (FRET) studies, we labeled separate pools of \(\text{PARLSkd3}\) with Alexa Fluor 488 (Alexa 488, ThermoFisher Scientific CAT# A20000) as the FRET donor and Alexa Fluor 594 (Alexa 594, ThermoFisher Scientific CAT# A20004) as the FRET acceptor. In brief, \(\text{PARLSkd3}\) (WT and mutants) was extensively exchanged into labeling buffer (LB; 50 mM HEPES-KOH [pH = 8.0], 150 mM KCl, 20 mM MgCl2, 10% glycerol, 10mM BME) at room temperature using Micro Bio-Spin 6 columns (Bio-Rad CAT# 7326200). \(\text{PARLSkd3}\) concentration was measured via A280 and the molar extinction coefficient and \(\text{PARLSkd3}\) concentration was adjusted to 30 μM. The primary amine (R-NH2) reactive dye, Alexa Fluor 488 NHS Ester (Succinimidyl Ester) (Alexa 488) or Alexa Fluor 594 NHS Ester (Succinimidyl Ester) (Alexa 594), was then added to \(\text{PARLSkd3}\) samples to achieve a 10-fold molar excess over \(\text{PARLSkd3}\). Samples were then incubated at 25°C in the dark. After 75min, the labeling reaction was quenched by rapidly and extensively exchanging into labeling buffer +10 mM DTT. To ensure that all unreacted dye is removed, the buffer exchange step was repeated at least twice. \(\text{PARLSkd3}\) concentration and labeling efficiency were determined by UV/Vis spectrometry according to the manufacturer’s instructions (Invitrogen). Typically, we achieved ~50% labeling efficiency.

**Fluorescence resonance energy transfer and subunit mixing**

We employed Förster resonance energy transfer (FRET) to measure subunit mixing (Figures S5D, 6A and 6B). Donor (Alexa Fluor 488) labeled \(\text{PARLSkd3}\) (Alexa 488- \(\text{PARLSkd3}\)), Acceptor (Alexa Fluor 594) labeled \(\text{PARLSkd3}\) (Alexa 594- \(\text{PARLSkd3}\)), or free dye were mixed in equal stoichiometric parts to a final total dye concentration of 1μM in labeling buffer with ATP (5 mM). Because these dyes function as an FRET pair with a Förster radius of 60 Å, primary amine labeling in \(\text{PARLSkd3}\) is expected to yield intermolecular FRET once mixed oligomers are formed. Given the R0 value of 60 Å for the Alexa 488-Alexa594 FRET pair, it is possible to observe both intrahexameric FRET (e.g. solvent exposed residues K538 from P3 and K658 from P4 are 8.5 Å apart) and interhexameric FRET within a dodecamer (closest two lysines are K134 to K265 at 22.4 Å apart, but it is unclear if they are solvent exposed). However, the hexameric state is the predominant species in the absence of substrate and thus our FRET assay likely reports on the hexameric state of \(\text{PARLSkd3}\) rather than the dodecamer (Figure 1B). A similar strategy has been employed to demonstrate the formation of mixed hexamers by bacterial ClpB (Werbeck et al., 2008), Hsp104 (DeSantis et al., 2012), and MCM helicase, another AAA + ATPase, from Sulfolobus solfataricus (McGeoch et al., 2005; Moreau et al., 2007). Prior to any measurements, samples were allowed to equilibrate for 10 min at room temperature. Mixed and equilibrated samples were excited at the donor excitation wavelength of 480nm. Donor fluorescence was measured at 519nm with a bandwidth of 5nm. Acceptor fluorescence was measured at 630nm with a bandwidth of 5nm. Apparent FRET efficiency (Figures S5D, S6C and S6D) was calculated from Alexa 488- \(\text{PARLSkd3}\) emission (488nm) and Alexa 594- \(\text{PARLSkd3}\)
emission (519nm) as $F_d/(F_d + F_a)$, where $F_d$ is the measured Alexa 488-PARLskd3 (donor) fluorescence and $F_a$ is the Alexa 594-PARLskd3 (acceptor) fluorescence in the presence of Alexa 488-Skd3.

**QUANTIFICATION AND STATISTICAL ANALYSIS**

Quantification is as described in the figure legends. Statistical analyses were performed using the GraphPad Prism (GraphPad Software, Inc.; La Jolla, CA, USA) as described in figure legends.
Supplemental information

Unique structural features
govern the activity of a human
mitochondrial AAA+ disaggregase, Skd3

Ryan R. Cupo, Alexandrea N. Rizo, Gabriel A. Braun, Eric Tse, Edward Chuang, Kushol Gupta, Daniel R. Southworth, and James Shorter
**Figure S1. Structure of PARL Skd3.** (A) FITC-casein binding analysis, measured by fluorescence polarization in the presence of no nucleotide (APO; grey), AMP-PNP (blue), ADP (red), ATP (green), and ATPγS (black). Values represent means ± SEM (n=3). (B, C) SEC-trace of
PARL Skd3 with different nucleotides without casein (B) and with casein (C) including AMP-PNP (blue), ADP (red), ATP (green), and ATPγS (black). The three vertical bars represent different molecular weight standards thyroglobulin (669 kDa), ferritin (440 kDa), and ovalbumin (43 kDa) that approximately represent Skd3 dodecamers (grey), hexamers (cyan), or monomers (magenta). (D) SEC-trace of PARL Skd3:casein:ATPγS complex with both 280nm UV absorbance (solid) and 495nm UV absorbance to detect FITC-casein (dashed) shown. Vertical bars indicate molecular-weight standards as in Figure S1B. (E) Representative 2D class averages from the full dataset. Scale bar, 100Å. (F) 3D classification results from the total combined dataset: hexamer, Class 1 (top, left); dodecamer, Class 2 (top, right); heptamer, Class 3 (bottom, left); and other, Class 4 (bottom, right). (G) SEC-MALS identifies the presence of dodecameric PARL Skd3 in solution. Left y-axis label and black circle traces represent relative protein concentration determined by relative absorbance at 280 nm (A280). Elution peaks for sizing standards are demarked with black triangles. Right y-axis label and hollow red circle traces represent molecular weight readings as measured by multi-angle light scattering. Red horizontal dashed lines demark the theoretical molecular weights of monomeric, hexameric, and dodecameric PARL Skd3. Related to Figure 1.
Figure S2. Structure and nucleotide-binding pockets of PARL Skd3. (A) Representative 2D class averages from the hexamer class. Scale bar, 100Å. (B) Gold standard FSC-curves for the hexamer class refinement. (C) Histogram and directional FSC plot for the hexamer class. (D)
Particle distribution map of the dodecamer class. (E) Local resolution map of the hexamer map and two different threshold high threshold (left) and low threshold (right). (F) PARL Skd3 structure labeled for reference with NBD helices and strands indicated for the large subdomain (D) or small subdomain (E) as for NBD2 of bacterial ClpB (PDB: 1QVR) (Lee et al., 2003). (G) Map vs. Model FSC for both unmasked (blue) and masked (orange) for the hexamer model. (H) Map plus model of alpha helix, D4, and beta-sheets d2, d3, and d6. (I) Schematic of NBD structure (top view) with circles representing ATP (green), ADP (grey), or APO (white) in the nucleotide-binding pocket (left). Map and model of the nucleotide-binding pocket with residues involved in ATP hydrolysis are shown and labeled including Arg Finger (R561), sensor-1 (N496), sensor-2 (R620), Walker A (K387), and Walker B (E455) (right).

Related to Figure 1 and 2.
Figure S3. Structural refinement of the ANK. (A) Representative 2D class averages from \textit{PARL}Skd3\textsuperscript{NBD}. Scale bar, 100Å. (B) Dodecamer map of \textit{PARL}Skd3 from 3D classification with representative model colored by individual domains docked in the top hexamer. The bottom
hexamer is colored by protomer. (C) Model prediction from Alpha-Fold of ANK colored by pLDDDT score. (D) Plot of the predicted aligned error of the Alpha-Fold prediction of full length Skd3. (E) Mask (pink) and map (grey) used in focus classification in cisTEM (Grant et al., 2018) of the single ankyrin domain on the hexamer class (left) with results of two representative classes (right). (F) Alignment of the four ankyrin repeats and the linker region of *H. sapiens* Skd3 to the consensus ankyrin repeat from Mosavi, *et al.* (Mosavi et al., 2002). Alignments were constructed using Clustal Omega. Linker region was aligned to consensus sequence manually. Bottom row shows consensus sequence of alignment. (G) Domain architecture maps of the different ANK deletion mutations. (H) Representative 2D class averages from the *PARL*Skd3Δ1-2 dataset. Scale bar, 100Å. (I) 3D classification results from the *PARL*Skd3Δ1-2 dataset: dodecamer, Class 1 (left); bent dodecamer, Class 2 (middle left); trimer, Class 3 (middle right); and other, Class 4 (right). (J) Gold standard FSC-curves for the final dodecamer class refinement. (K) Histogram and directional FSC plot for the dodecamer class. (L) Local resolution map of the dodecamer map. (M) Particle distribution map of the dodecamer class. Related to Figure 3.
Figure S4. Structural features of the NBD insertion and CTD. (A) Alignment of a select region of the NBD from *H. sapiens* Skd3, NBD2 from *E. coli* ClpA, NBD2 from *E. coli* ClpB, NBD2 from *A. aureus* ClpC, NBD from *E. coli* ClpX, NBD2 from *S. cerevisiae* Hsp78, NBD2 from *A. thaliana* Hsp101, NBD2 from *S. cerevisiae* Hsp104, NBD from *E. coli* RuvB, and NBD2 from *P. aeruginosa* ClpG. Alignments were constructed using Clustal Omega. Bottom row shows consensus sequence of alignment. Highlighted in blue are the sensor-1 and Arg-finger motifs. Light blue highlights the insertion from L507-I534 in the Skd3 NBD. (B) Alpha-fold model prediction (grey) of the NBD insertion alone (residues 449-515 to 535-552 are shown). The residues that were successfully built in de novo are represented in green on the model of protomer 3. (C) The Alpha-fold model prediction (black) overlayed with the Hsp104 model (grey, PDB: 5VJH). (D) SEC of PARL Skd3ΔL507-I534 plus ATPγS with casein (dashed) and without casein (solid). The three vertical bars represent different molecular weight standards thyroglobulin (669 kDa), ferritin (440 kDa), and ovalbumin (43 kDa) that approximately represent Skd3 dodecamers (grey), hexamers (cyan), or monomers (magenta). (E) SEC of
PARL$^{\text{Skd3}^\text{AL660-1707}}$ plus ATP$\gamma$S with casein (dashed) and without casein (solid). The three vertical bars represent different molecular weight standards thyroglobulin (669 kDa), ferritin (440 kDa), and ovalbumin (43 kDa) that approximately represent Skd3 dodecamers (grey), hexamers (cyan), or monomers (magenta).

Related to Figure 4.
**Figure S5. Skd3 is a subglobally cooperative protein disaggregase.** (A) ATPase activity of \( \text{PARL}_{\text{Skd3}} \) and Alexa594-\( \text{PARL}_{\text{Skd3}} \). ATPase activity was compared to buffer using one-way ANOVA and a Dunnett’s multiple comparisons test (\( n = 3 \), individual data points shown as dots, bars show mean ± SEM, ****\( p<0.0001 \)). (B) Luciferase disaggregate activity of \( \text{PARL}_{\text{Skd3}} \) and
Alexa594-PARLSkd3. Luciferase activity was buffer subtracted and normalized to PARLSkd3. Disaggregase activity was compared to buffer using one-way ANOVA and a Dunnett’s multiple comparisons test (n = 3, individual data points shown as dots, bars show mean ± SEM, ****p<0.0001). (C) Schematic of subunit mixing assayed by FRET. Separate pools of PARLSkd3 were labeled with Alexa-Fluor 488 (Alexa488) to serve as a donor and Alexa-Fluor 594 (Alexa594) to serve as an acceptor. In mixed hexamers, the donor (Alexa488) and acceptor (Alexa594) labels come into close enough proximity to elicit FRET. (D) FRET efficiency after mixing Alexa488-PARLSkd3 with buffer, Alexa594-PARLSkd3, Alexa594-PARLSkd3K387A, Alexa594-PARLSkd3E455Q, or Alexa594-PARLSkd3Y430A for 10 min in the presence of ATP (5 mM) at a 1:1 molar ratio with a final labelled PARLSkd3 concentration of 1μM. As a negative control the FRET efficiency of mixing unreacted Alexa488 dye with unreacted Alexa594 dye is also shown. Relative FRET efficiency was compared to WT PARLSkd3 using one-way ANOVA and a Dunnett’s multiple comparisons test (n = 3, individual data points shown as dots, bars show mean ± SEM, ****p<0.0001). (E) ATPase activity of PARLSkd3 mixed with various ratios of buffer. ATPase activity was buffer subtracted and normalized to PARLSkd3 (n = 3, data shown as black dots with mean ± SEM). (F) Luciferase disaggregase activity of PARLSkd3 mixed with various ratios of buffer. Disaggregase activity was buffer subtracted and normalized to PARLSkd3 (n = 3, data shown as black dots with mean ± SEM).

Related to Figure 6.
Figure S6. SCN-linked subunits inhibit PARL Skd3 activity more severely than MGCA7-linked PARL Skd3 subunits. (A) SEC of MGCA7-linked PARL Skd3 variants. The three vertical bars represent different molecular weight standards thyroglobulin (669 kDa), ferritin (440 kDa), and ovalbumin (43 kDa) that approximately represent Skd3 dodecamers (grey), hexamers (cyan), or monomers (magenta). (B) SEC of SCN-linked PARL Skd3 variants. The three vertical bars represent different molecular weight standards thyroglobulin (669 kDa), ferritin (440 kDa), and ovalbumin (43 kDa) that approximately represent Skd3 dodecamers (grey), hexamers (cyan), or monomers (magenta).
monomers (magenta). (C) FRET efficiency after mixing Alexa488-\textsc{parl}Skd3 with buffer, Alexa594-\textsc{parl}Skd3, Alexa594-\textsc{parl}Skd3\textsuperscript{A591V}, or Alexa594-\textsc{parl}Skd3\textsuperscript{R475Q} for 10 min in the presence of ATP (5 mM) at a 1:1 molar ratio with a final labeled \textsc{parl}Skd3 concentration of 1\textmu{}M. Relative FRET efficiency was compared to WT \textsc{parl}Skd3 using one-way ANOVA and a Dunnett’s multiple comparisons test (n = 3, individual data points shown as dots, bars show mean ± SEM, ****p<0.0001). (D) FRET efficiency after mixing Alexa488-\textsc{parl}Skd3 with buffer, Alexa594-\textsc{parl}Skd3, Alexa594-\textsc{parl}Skd3\textsuperscript{R408G}, Alexa594-\textsc{parl}Skd3\textsuperscript{N496K}, Alexa594-\textsc{parl}Skd3\textsuperscript{R561G}, or Alexa594-\textsc{parl}Skd3\textsuperscript{R620C} for 10 min in the presence of ATP (5 mM) at a 1:1 molar ratio with a final labelled \textsc{parl}Skd3 concentration of 1\textmu{}M. Relative FRET efficiency was compared to WT \textsc{parl}Skd3 using one-way ANOVA and a Dunnett’s multiple comparisons test (n = 3, individual data points shown as dots, bars show mean ± SEM, **p<0.01, ****p<0.0001). (E-H) ATPase activity of \textsc{parl}Skd3 was mixed with various ratios of \textsc{parl}Skd3\textsuperscript{A591V} (E) or \textsc{parl}Skd3\textsuperscript{R620C} (G). ATPase activity was buffer subtracted and normalized to \textsc{parl}Skd3 (n = 3, data shown as black dots with mean ± SEM). Luciferase disaggregase activity of \textsc{parl}Skd3 mixed with various ratios of \textsc{parl}Skd3\textsuperscript{A591V} (F) or \textsc{parl}Skd3\textsuperscript{R620C} (H). Disaggregase activity was buffer subtracted and normalized to \textsc{parl}Skd3 (n = 3, data shown as black dots with mean ± SEM). (I) Table summarizing the effect of MGCA7-linked subunits on ATPase activity and luciferase disaggregase activity. (J) Table summarizing the effect of SCN-linked subunits on ATPase activity and luciferase disaggregase activity. Related to Figure 7.
|                          | PARL\textit{Skd3}  | PARL\textit{Skd3}  | PARL\textit{Skd3}  | PARL\textit{Skd3}  |
|--------------------------|----------------------|----------------------|----------------------|----------------------|
|                          | (Class 1, AAA+ only) | (Class 1, AAA+ & ANK) | (Class 2)           | ∆1-2 (Class 1)       |
| EMDB                     | 26121                | 26122                |                      |                      |
| PDB                      | 7TTR                 | 7TTS                 |                      |                      |

**Data collection and processing**

|                            | PARL\textit{Skd3}  | PARL\textit{Skd3}  | PARL\textit{Skd3}  | PARL\textit{Skd3}  |
|---------------------------|----------------------|----------------------|----------------------|----------------------|
| Microscope and camera     | Titan Krios, K3      |                      | Glacios, K2          |                      |
| Magnification             | 105,000              |                      | 45,000               |                      |
| Voltage (kV)              | 300                  |                      | 200                  |                      |
| Data acquisition software | Serial EM            |                      | Serial EM            |                      |
| Exposure navigation       | Image Shift          |                      | Image Shift          |                      |
| Electron exposure (\text{e}^-/Å^2) | 68                  |                      | 55.8                 |                      |
| Final particle images (no.) | 358,000             | 130,000              | 165,354              |                      |
| Map resolution (Å)        | 2.96                 | ~6 (filtered)        | 7.2                  | 7.9                  |
| FSC threshold             | 0.143                |                      |                      |                      |
| Map resolution range (Å)  | 2.5-6.5              | 6                    | 6-10                 | 6-20                 |

**Reefinement**

|                            | PARL\textit{Skd3}  | PARL\textit{Skd3}  | PARL\textit{Skd3}  | PARL\textit{Skd3}  |
|---------------------------|----------------------|----------------------|----------------------|----------------------|
| Model resolution (Å)      | 2.9                  | 2.9                  | -                    | -                    |
| FSC threshold             | .143                 | .143                 | -                    | -                    |
| Map sharpening B factor (Å^2) | -119           | -                    | -497                 | -610                 |

**Model composition**

|                            | PARL\textit{Skd3}  | PARL\textit{Skd3}  | PARL\textit{Skd3}  | PARL\textit{Skd3}  |
|---------------------------|----------------------|----------------------|----------------------|----------------------|
| Non-hydrogen atoms        | 15,699               | 18,796               | -                    | -                    |
| Protein residues          | 1926                 | 2700                 | -                    | -                    |
| Ligands                   | 9                    | 9                    | -                    | -                    |
| B factors (Å^3)           | -                    | -                    |                      |                      |
| Protein                   | 158.16               | 178.33               | -                    | -                    |
| Ligand                    | 54.10                | 54.10                | -                    | -                    |

**R.m.s. deviations**

|                            | PARL\textit{Skd3}  | PARL\textit{Skd3}  | PARL\textit{Skd3}  | PARL\textit{Skd3}  |
|---------------------------|----------------------|----------------------|----------------------|----------------------|
| Bond lengths (Å)          | .011                 | .010                 | -                    | -                    |
| Bond angles (°)           | 1.249                | 1.222                | -                    | -                    |

**Validation**

|                            | PARL\textit{Skd3}  | PARL\textit{Skd3}  | PARL\textit{Skd3}  | PARL\textit{Skd3}  |
|---------------------------|----------------------|----------------------|----------------------|----------------------|
| MolProbity score          | 1.67                 | 1.53                 | -                    | -                    |
| Clashscore                | 6                    | -                    | -                    | -                    |
| Poor rotamers (%)         | .30                  | .30                  | -                    | -                    |

**Table S1.** Cryo-EM data collection, refinement and validation statistics of \textit{PARL}\textit{Skd3} structures.

Related to Figures 1, 2 and 3.